<SEC-DOCUMENT>0001087294-14-000019.txt : 20140509
<SEC-HEADER>0001087294-14-000019.hdr.sgml : 20140509
<ACCEPTANCE-DATETIME>20140509171542
ACCESSION NUMBER:		0001087294-14-000019
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20140509
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20140509
DATE AS OF CHANGE:		20140509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		14830175

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8kstubforcetinvestmentand.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>8k stub for CET investment and Vaprisol launch</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s66c5a327477a4a01a1c0a52e78e5eccd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="51%"></td><td width="5%"></td><td width="44%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 9, 2014 (May 6, 2014)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="0%"></td><td width="33%"></td><td width="18%"></td><td width="5%"></td><td width="11%"></td><td width="33%"></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s66c5a327477a4a01a1c0a52e78e5eccd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 6, 2014, Cumberland Pharmaceuticals Inc. (the "Company") and China's Gloria Pharmaceuticals Co. issued a press release announcing a joint research and development initiative.  A copy of the press release is furnished as Exhibit 99.1.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 6, 2014 the Company issued a press release announcing the launch of its active promotional campaign to support its new Vaprisol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;product.  A copy of the press release is furnished as Exhibit 99.2.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s66c5a327477a4a01a1c0a52e78e5eccd"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="68%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">May 9, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 6, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 6, 2014</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991-cetinvestment.htm
<DESCRIPTION>EXHIBIT 99.1 CET INVESTMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>Exhibit 99.1 - CET investment</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s619c6484521f46918da6366f41f36f4b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">FOR IMMEDIATE DISTRIBUTION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><img src="cumberlandpicture.jpg" style="height:72px;width:321px;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;</font><img src="newgloriapicture.jpg" style="height:81px;width:257px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS AND GLORIA PHARMACEUTICALS </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ANNOUNCE JOINT RESEARCH &amp; DEVELOPMENT INVESTMENT</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NASHVILLE, Tenn</font><font style="font-family:inherit;font-size:12pt;">. </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(Tuesday, May 6, 2014) - </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NASDAQ:CPIX</font><font style="font-family:inherit;font-size:12pt;">) and China&#8217;s Gloria Pharmaceuticals Co. (</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SHE: 002437</font><font style="font-family:inherit;font-size:12pt;">) announced today a joint research &amp; development initiative. Each company has made a $1 million investment in </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Cumberland Emerging Technologies</font><font style="font-family:inherit;font-size:12pt;">&#32;(&#8220;CET&#8221;), which is majority owned by Cumberland and partners with academic research centers to develop promising biopharmaceutical technologies. The new funds will be used to accelerate development of CET&#8217;s pipeline of new product candidates emerging from Vanderbilt University and other regional research centers.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CET was established among Cumberland Pharmaceuticals, Vanderbilt University and the state of Tennessee to support the development of biopharmaceutical product candidates.  Gloria will have the first opportunity to negotiate a license to CET products for China, and Cumberland will retain access to CET&#8217;s product rights for the rest of the world.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We believe CET represents a unique partnership among academia, government and industry,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We welcome Gloria as our international partner, shareholder and fourth constituent. Together these four partners can help develop and commercialize bio-pharmaceutical research and deliver new products to improve patient care.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Gloria Pharmaceuticals is a leading provider of pharmaceutical products to China&#8217;s hospitals.  Cumberland and Gloria had previously entered into an exclusive licensing agreement to bring Cumberland&#8217;s Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;and Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;products to hospitals and patients in China.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We are delighted to expand our relationship with Cumberland in this Research and Development venture with the goal of developing innovative new medicines for the benefit of patients worldwide,&#8221; said Zhu JiMan, Chairman of Gloria Pharmaceuticals.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Cumberland Emerging Technologies Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Emerging Technologies Inc. (&#8220;CET&#8221;) is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc., and the state of Tennessee&#8217;s Launch TN (formerly the Tennessee Technology Development Corporation).  The mission of CET is to advance biomedical technologies and products conceived at academic research centers towards the commercial marketplace.  CET manages the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing, and market issues that are critical to successful new biomedical products. </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s619c6484521f46918da6366f41f36f4b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CET has sponsored Middle Tennessee&#8217;s first life sciences incubator located in downtown Nashville adjacent to the Union Station Hotel and the Frist Visual Arts Center.  This Life Sciences Center provides laboratory space, equipment and other support to a growing number of tenants who specialize in medical products and research advancements.  For more information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.CET-Fund.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of hyponatremia and Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;for the treatment of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;and duodenal ulcer disease. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company&#8217;s website </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Gloria Pharmaceuticals Co. Ltd.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Gloria Pharmaceuticals focuses on the research, development, and commercialization of injectable drugs in a variety of categories including antibiotics, medical nutrition, orthopedics, rheumatology, oncology, gastroenterology and cardiovascular medicine. Established in 2000, the Company is based in Beijing, China, and primarily sells its products throughout China&#8217;s hospital market. For more information, please visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.gloria.cc</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s619c6484521f46918da6366f41f36f4b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investor Contact:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Elizabeth Davis</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Cumberland Pharmaceuticals</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">615-255-0068</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">investors@cumberlandpharma.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Media Contact:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Rebecca Kirkham</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Lovell Communications</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">615-297-7766</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">rebecca@lovell.com</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit992-vaprisollaunch.htm
<DESCRIPTION>EXHIBIT 99.2 VAPRISOL LAUNCH
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>exhibit 99.2 - Vaprisol Launch</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sd2174c057c714f698cc1d1d9fb78902e"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;FOR IMMEDIATE DISTRIBUTION </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">&#32;</font><img src="cumberlandpicture.jpg" style="font-size:24pt;height:84px;width:370px;"></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS  </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LAUNCHES VAPRISOL</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;PROMOTION</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">-Vaprisol marks new product for hospital sales force </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tennessee, (Wednesday, May 7, 2014)</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">-Cumberland Pharmaceuticals Inc. </font><font style="font-family:inherit;font-size:12pt;">(NASDAQ:CPIX) today announced the launch of its active promotional campaign to support its new Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;product. Cumberland will promote Vaprisol across the United States through its hospital sales force. A National Sales Meeting was convened this week to officially launch active promotion and other efforts to support the brand.  Cumberland acquired Vaprisol from Astellas Pharma US earlier this year and has been distributing the product since.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with hyponatremia. It is one of two branded prescription products indicated for the treatment of hyponatremia, and is the only intravenous brand available.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Hyponatremia is a common electrolyte disturbance in hospitalized patients, in which sodium ion concentration in blood plasma is lower than normal.  This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Vaprisol offers reliable, defined control with convenient pre-mixed IV dosing for patients with euvolemic and hypervolemic hyponatremia.  This product compliments the activities of the Company&#8217;s hospital sales force which also promotes Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;and Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;A key component of our growth strategy is to acquire approved brands with market potential that can be unlocked through the active promotional efforts of our sales organization,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We believe Vaprisol reflects our mission to help improve patient care.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Vaprisol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Vaprisol an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal.  This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.  The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion.  Vaprisol does not require dilution and has a well-defined daily dose of 10 mg, 20 mg, or 40 mg. Vaprisol was approved by the U.S. Food and Drug Administration in 2005 for euvolemic hyponatremia and in 2007 for hypervolemic hyponatremia. For full prescribing information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.vaprisol.com</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sd2174c057c714f698cc1d1d9fb78902e"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Acetadote</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death.  For full prescribing information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.acetadote.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Caldolor</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.caldolor.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of hyponatremia and Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;for the treatment of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;and duodenal ulcer disease. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company&#8217;s website </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sd2174c057c714f698cc1d1d9fb78902e"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Important Note Regarding Forward-Looking Statements </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # # </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contacts: </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Investors:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Elizabeth Davis</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">615-255-0068</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">investors@cumberlandpharma.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Media:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rebecca Kirkham</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lovell Communications</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">615-297-7766</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">rebecca@lovell.com</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>cumberlandpicture.jpg
<TEXT>
begin 644 cumberlandpicture.jpg
M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`#3`Z`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]]****`"B
MBB@`HHHH`****`"BBB@`HHI&<*"3VH`6BOG'Q#^TP-7_`."GGAOX5:=J4_E:
M5X#O_$&KVL4Q$9DFO+6&W\Q0<%E6.8C/($G'WN?HZM:M%TU'FZJY$*D9WY>@
M4445D6%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44$X'-->3:A
M.1P,B@!U%>5?$#]LOX?_``WN9[6[\06VHZA;$K)8Z3$^H7,9]&2$,4_X%C\*
M\*^*7_!6^/PY%(OA[P#J%XPR%FU:_CLD^NR/S6_`[3770P->LTH1_3\R934=
M6?8[7"+U8#!QR:\`_;M_X*)_#[]A3X>7FH^)-5@NM=>%CIN@VLJM?7\FT[1L
MY*1YZR,`H]SQ7YZ_M'_\%:?C1XVM+BUT[5M*\'6DFY=NB6>+@J>S33-(V?=`
MAK\ZOC=K-[XGU6]U'4[V\U+4+QB\]U=S-//,WJSL2S'ZFOH\MX4E4FI8F5H]
MEU/.QF.]G%N!]M_\$'?V@_$'[5?_``6&^(_CWQ3.)M7\1>&+R>15SY5NGVFT
M5(4'9$0*H]A[U^XU?@#_`,&PXQ_P47\2_P#8G77_`*56M?O]7/Q;3C#'\D59
M*,4C#(9.6&O+75_F%%%%?,GM!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!110
M3@?2@`J#4M1BTJS>XGDCBAB!9WD<*J*!DDD\``5Y]^T3^TSX7_9S\)+J>OW3
M_:)RR6&GV^'N]1E`SLB3(SC/+$A5!R2!7QEXX^./B7]IS5A)XG>.VT$2;K;P
M];RL]FG(PT[$#[2_?Y@$4]%R-Q[,+@IUES[1[_Y$2J):'T_XH_;+A\52R6'P
M]TQ/$;ABC:O<RFWTJ(@\E&`+W&/2,;#T\Q:Y?Q-X%U'QMI#7'B_Q%J/B$R#<
MUC'_`*%I:^PMT.7'M,\E<]\.3^[C`X```'85Z3K/_(`_X#_2JJ)4Y)4_^#_7
MH"5]6?/OQ!TFUT&Q%I96\%I:PC;'%"@1$`[`#@"OFGXJ]9/K7T_\5_O2?C7S
M!\5>LGUKZ/+=;7,*VB/FOXH?ZQZ^>/BE_JY?Q_E7T/\`%#_6/7SQ\4O]7+^/
M\J^SP?0\3&_`SZK_`.#8C_E(OXD_[$ZZ_P#2JUK]_J_`'_@V(_Y2+^)/^Q.N
MO_2JUK]_J^$XQ_Y&+_PHZ>'_`/=?F_S"BBBOECW`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@!&8(N2<`5X_\`MC_M?:#^R1\-FU?4"+[5[_=;Z1I2/MEU&<#.
M,_PQJ,%W/"CU)4'T#XJ_$K1OA#\.M:\3:_>Q6&D:%:O>7<SG[J*,X`ZECP`H
MY)(`Y-?B#\=_VG-9_:X^-]_XPUAI(893]GTNP+Y33+-6^2(=MQ^\[?Q,3V"@
M>SE&5O%3<Y?!'?S\CFKUN33J>C:E\4=?^-_Q"NO%/BB_.HZS??)N"E(;6($E
M8(4R=D8].K')8DG->M_#O[D7U%>"_#P;O+QSTKVSP1XFL=/O(;1YUEOGP4LX
M$:>ZE_W(8P9&_!37TN,IQ@DDK6_`RIZ[GT;\.?N1_05Z3K/_`"`/^`_TKS/X
M:^'/&NJ0(^F^`O$3Q\8FU+RM,B/_``&9A,/^_1KTE?A!\2O$EH(KBY\'>'HN
M,JL5SJLF/KFW4'\Z^1KI<]^9?>=46TCP?XL.`S\^M?,/Q6X,F?7-?H)=?L%C
MQ#('UGQSXGG9N7CL;.SMH3]`\,CC_OL_6GP?\$P?A1<X.IV7B+5Y!U:XURYB
M#_5871?TKT\+F5"C;F;?HO\`.QG*$IZ(_&7XH#]Y)[5\[_%-L)+P>_:OZ,+7
M_@F'\"+:0,WP[TN[8=[NYN;K_P!&2-5I?^":?P"`.[X1^!9<]?-TJ*3_`-"!
MKV*7%F&I[0;^XX:^7SG&US\</^#8MQ'_`,%%_$N3C_BCKKCO_P`?5K7[_;AC
M-?GI_P`%)_V:?`'[,.@^$M3^'7A#0/`^HZA<W,%S<Z)9I8S3QB-#L9XP"5S@
MX)QQ7RA%\:/&.BR!K3Q9XEMBG(\O5)UQ^35\WG>9QQV)]O"-E9+7R-LMP<L-
M1]G+75_B?MV2!U-&><5^,FC?MT?%WP<X-CX^U\XYVW,JW2_B)0V?QKT;P)_P
M66^*GA"2--8M?#GB6$<.9K4VTS#V:(A1^*'Z5Y!Z!^JM%?$_PI_X+<^`_$K1
M6_BS1-8\+SM@//$/MMLOOE0'Q_P`U]4_"?X]>#?CCI1O/"?B71]>B49=;6X5
MI8O]^/[Z'V8"@#KZ*`<T4`%%%%`!1110`444-P#GI0`45\T?\%#/^"J/PM_X
M)O>'=/G\;:C=7FM:PK/IVAZ9&L]]=JIP9""RJD8/&]V`)!`R0<?"-W_P=U^$
M([IQ!\&?$LL&?D:37((W(]P(F`_,UZF$R3'8FG[6C3;7?1?F>?7S3"T)>SJU
M$GV/V%HK\=Q_P=W^%/\`HBOB#_PH(?\`XS1_Q%W^%/\`HBGB#_PH(?\`XS77
M_JOFG_/I_>O\SG_M[`?\_5^/^1^Q%&>:_'?_`(B[O"G_`$13Q#_X4$/_`,9K
ML/@S_P`'7GPE\;^*;:P\7>!_%G@JTN)%0WZRQ:E!!DXW.$VN`/55:HGPUF<8
M\SI/[T_U*AGF!DTO:K\3]6**R?!'C;2?B-X3TW7=#U"TU72-8M8[RRO+6420
MW4,BADD1AP5((((]:UJ\-IIM,]5.ZT#/-&:^9/\`@J-_P4@L?^"9?P6TGQIJ
M/A>]\66VJZNFE"UMKM;9D+122;]S*PQ^[QC'>OGS_@GK_P`'#&A_\%!/VI=%
M^&.G?#35_#5SJ]M=7"WUQJT=RD8@A:4@H(E)R%(Z\5Z%+*L54P[Q4(>XMWIT
MW..IF&'IUE0E/WGT]=C]'J***\\[0HSBBN(_:-^,2?L^_`WQCXXELI=2@\(:
M)=ZS):QN$>X6")Y"@8@@$[<9(-.,7)J,5JQ-V5V=OFBOQYM?^#N3PMJ%[#`G
MP7\0)YKA,G7X3C)`_P">-?L)$Q:-21@D#(]*[,;EN*P=OK,>6^QR87'T,3?V
M$KVW'445\O?\%3?^"EUC_P`$Q/A)H/B[4?"EYXLM];U8:6+>VO%M6B8Q22;B
MS*P(^3&,=ZPP^'J5ZBI4E=O9&]:K"E!U*CLD?4-%?GE_P3J_X.%O`G[?GQW_
M`.%?S>%K[P#K%[;--I+7VHQW,>J2*<O`K!%VN$^8`YW8('(P?T,5PW0@_C6F
M,P=;"U/98B/*R,+BJ6(A[2E*Z%HHHKE.@***\C_;<_;$\+_L-?LZZ[\1?%$P
M:QT>,+!:1N!-J-RW$5O'G^)C^0!/05=.G*I-4X*[>Q,YQA%SD[)'KF:*_(7P
MC_P=D^%_%WBS2M(C^#6OV\FIWD-H)3KT3",R.$W$>3R!G.,U^N]N[20J6&&(
MYKKQN6XK!M+$PY;['+@\=0Q,7*C+FL/HS01D5\I?\%5?^"H>G_\`!+KX>^%O
M$.H^$KWQ=%XHU&33DAM[U;4P,D1DW%F1L@@8Q7/A\/4KU%2I*\GL;UZT*,'4
MJ.R6Y]6T5^.X_P"#NWPJ3C_A2GB'_P`*"'_XS1_Q%W^%/^B*>(/_``H(?_C-
M>S_JQFG_`#Z?WK_,\S^WL!_S]7X_Y'[$45^._P#Q%W^%/^B*>(/_``H(?_C-
M'_$7?X4'_-%/$'_A00__`!FC_5C,_P#GT_O7^8?V[@?^?J_'_(_8BC/.*_'_
M`$G_`(.Z/!-QJ4*7WP<\46MH6Q)+!K,$[H/4*8U!^FX5^B7[#7[??P[_`."@
M?PN/BKX?ZL;N&V<0ZA87,?DWNES$9$<T>3C(SA@2K8.":XL9DV-PL?:8BFU'
MONOO1TX7,\+B)<E*HF^Q[=10#D9'(--E)6)B.H'%>:M3O'9HK\DOBA_P=:>&
M/A?\2_$?AJ?X/:[>R^'M4N=,>=-=B03&&5HRP7R3C.W.,]ZQ!_P=W>%#_P`T
M4\0?^%!#_P#&:]V/#.9R2E&E=/S7^9Y#SW`IM.HE;O<_8BBOQW_XB[_"@./^
M%*>(/_"@A_\`C-'_`!%W^%/^B*>(/_"@A_\`C-5_JQFG_/I_>O\`,7]O8#_G
MZOQ_R/V(HK\=S_P=W^%!_P`T4\0?^%!#_P#&:[K]F+_@YZ\._M.?M$^"OA[9
M_";6](N/&6KV^DQWDNM13);-,X0.4$0)`STS45.&\RA%SE2LEYK_`#*AG>"E
M)1C55WZGZG4$X%(IR!GK7'?M%?%N/X`_`#QOX[ELI-1A\%Z#>Z[):(X1KE;6
M!YC&&((4L$(R0<9KQ8Q<FHQW9ZDI**;?0[*BOQT7_@[L\*+_`,T5\0?AX@A_
M^,T__B+N\*?]$4\0?^%!#_\`&:]S_5C-/^?7XK_,\IY[@/\`GZOQ/V(HK\=_
M^(N_PI_T13Q!_P"%!#_\9H_XB[_"F?\`DBGB#_PH(?\`XS3_`-6,T_Y]/[U_
MF+^WL#_S]7X_Y'[$9YHK\>K/_@[L\'2WT2W/P:\30VY8"1XM;@D=%[D`QJ&/
ML2/K7Z`_L#_\%*/AO_P48^'MWKG@#4+D7&DR)%JFE7\0AOM-=P2N]`Q!5L-M
M=25.UAG((KDQF2X["Q]I7IM1[[K\#IPV9X6O+DI339]"4=**CN79$&WJ3BO+
M.\DS17Y1_'[_`(.E?#?P'^-_C#P//\(M=U"Y\(ZS=Z/)=IKD4:W#03-$7"F(
MX!VYQDU]_?L'_M7V_P"W#^REX3^*5IHT_A^V\5I<21V$TXG>W$5S+;G+@*#D
MQ$\#O7?BLKQ>'I1KUX6C+;Y['%0S'#UJCHTY7DMSUZBBBN`[0HHHH`****`"
MBBH-1OH].L9;B61(H85WR.[`*BCJ23P`!WH`GSBBOR0^)7_!V1X%\&>/];TC
M2/A=K?B33M,O9K6UU2/68[=-01&*B54,1*JV,C)Z$5]V_P#!-_\`X*#^&?\`
M@HY^SQ%X[T&W;2)XKR6PU#29[A99].F0@@,0!D,A5U.!D-Z@UZ6+R?&X>FJU
M:FU%G!ALRPU>;ITYIM=#Z"HHHKS3O"@G%%)(2J$@$D#C%#V`6BOS6_;R_P"#
MB_0OV%/VIO$GPQU#X8:QXBN?#PMRU_!J\=NDPE@2480QL1C?CKVKZA_X)V?\
M%)/`/_!1OX0KXE\*7:V6J6F(]7T*YE4WFDR^C`?>0_PR`88>AR!Z%;*L72HK
M$U(6@]GZG#1S'#U:KH0G>2Z'T110"&&0<BBO/.X***\^_:K^/$?[,/[.OC'X
M@S:=)J\'A#2I]4DLXY1$]PL2[BH8@A2?4BJA"4Y*$5=O0F4E&+E+9'H.:*_*
M?]GC_@Z.\-_M!?'?P9X$MOA'KFFW/C#6K31H[N37(I$MVGF6(.5$0)`W9QGM
M7ZJP,7A4GKWKKQN7XC"24<1'E;U6WZ'-A,;1Q,7.A+F2'T$XHKF_B_X_'PK^
M&'B'Q*UNUW'X>TRYU-X%;:TRP1-(5![$A<9]ZXTFVDCJ;25V=)17XZI_P=V^
M%`@)^"GB#T/_`!4$/_QFG?\`$7=X4_Z(IX@_\*"'_P",U[O^K&:=:7XK_,\E
MY[@;_P`5?B?L117X[_\`$7?X4(_Y(KX@_P#"@A_^,T0_\'=GA)YP)/@QXD2/
MN5UZ!C^1A'\Z/]6,T_Y]/[U_F"SW`?\`/U?C_D?L117YG?"+_@Z:_9\\>ZA#
M;>(M,\;^"3*0IN+W3X[NWC/N;=W?'OL_"OO;X"_M*>!OVG?!4/B/P%XKT3Q7
MHLWRFYT^Y641/_<=?O1N.ZN`1Z5YV*RW%X7_`'BFXKO;3[]CMP^.P^(_@S3?
M:^IW=%(&##(((J&_U"'3K:26:6.&.)"[.[!54`9))/0<5Q'5>Q.3BC-?(6H?
M\%A/!GB/Q%?V/PW\$_%/XRVVE3-!>:IX,\-R7FEQ2*3E%NG9(Y&_ZYEL]LUZ
M/^RK_P`%#/AY^UCXBU+P]I-UJWA[QIH<?F:GX5\2:=)I.M6*\?.UO+@LG(^=
M"RC(R1FNJ>!Q$(>TG!I+?^NASQQ5*4N521[M12!@PR""#2URG0%%%0:E,MM:
M-([!$C&YF/\`"!UI!?N?F+_P7X_:KD_MOP_\']+NML3(FN:\%;&X9(M86_X$
MK2D>T9KY1_91_9L\<?M):X;+P=H,^J);/LN;V1O)L;,]<2S$8#8.=B[GQ_#7
MLO[+O[&>I?\`!5?]L7X@?%GQ1->6'PXDU^9(9D)6;65A8116\3?P(D,<8=QR
M#E1\V67];?AM\.-%^$O@VS\/^'=+L=&T?3D\NVM+2(1Q1+]!W)Y)/))YS7VE
M;,J>78>.$H*\UK+U>_J>;2I2K3=66W0^3OV>O^"1&A^&;..Z\>^(+_Q%>@#=
M8:<[6-@GLS*?.D^N]%(_@KZF^'OP7\+_``GTT6?AK0M)T.WP`5L[5(B^.[$#
M+'W))KJ**^5KXRM6=ZDKG?&G%;"*-J@>E+117,6%%%%`!1110!\5_P#!9S_D
M1?`W_7_=?^BDK\\[_J:_0S_@LY_R(O@;_K_NO_125^>=_P!30!E7G4_2LFZ^
M^?K6M>=3]*R;K[Y^M`&5=_Q?Y[5!HOBO4_!>M1:CH^H7NEW]NVZ.XM9FBD0^
MS*014UW_`!?Y[5DWGWC0!]S?LG?\%B_&W@HV^G^.[=?&&E*`INU`BU&(=,[A
M\LGT8`G^]7Z+?`O]I#PC^T5X?%_X6U6&\"*#/;-^[N;0G^&2,\K]>A[$U^$?
M@SJGUKVGX0^+=4\">(+75=&O[K3-1M3F*XMW*.N>H]U/=3D'N*`/VNHKYL_9
M*_;JM_BFUKH/BT0:;XB<".WNDPEKJ1]!_P`\Y#_=)(/\)_A'TDC;U!Z4`+11
M10`4V;F%^<<'FG4C_</TII`?S!_\'"?Q*O/B)_P56^(<%S</-;^&%LM'LUW9
M6&-+6.1E`[?/*Y/N37J/_!,[_@WS3_@H=^RMIOQ+;XIMX4.H7MU9_8!X?^V!
M/)D*9\SSTSG&?NUX%_P6]_Y2L?&G_L-K_P"D\-?M3_P;._\`**GPU_V&]4_]
M*&K]4S+&UL#DU&>%ERMJ/1/=7Z^A^?9?AJ>*S6M#$+F2YG^-CY5_XA#8C_S7
MEO\`PD?_`+KH_P"(0V'_`*+RW_A)?_==?M517Q:XJS3_`)^_A'_(^G_U>R__
M`)]K\?\`,_%4_P#!H="!C_A?+G_N4O\`[KK\Q/\`@HA^QX/V#OVL?$7PQ&OG
MQ-_8,=N_]H&T^R^=YL"2X\O>^,;\?>/2OZY3R#7YK_M^_P#!NAHW[>7[4OB#
MXG7OQ3U3PW<:\ENC6$.BQW*0^5"D7#F52<[,].]>SD?%M95W_:%3W+=EOTV5
MSR\UX<I.BOJ<$I7[O;YLW/\`@V4^)U[\0?\`@F7IUA?3O._A37+[28"Y)*P9
MCG1?HIG8>P`%?H97S9_P2_\`^"=EG_P31^`M]X$L?%%UXLAO=6EU7[9/9K:L
MIDCB39L#-P/+ZY[U])U\GF=:E6Q=2K1^%MM'T>7TZD,/"%7XDE<_+C_@Z_\`
M^3#O"'_8Y0?^DMQ7YR?\&V'_`"EE\%?]@O5O_2&:OT;_`.#K_P#Y,.\(?]CE
M!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J^^RG_`))VKZ3/C\T_Y'-'_MW\S^F*
MBBBOS,^["O$O^"DG_)@'QN_[$76/_2*:O;:\2_X*2?\`)@'QN_[$76/_`$BF
MKHPG\>'JOS,J_P##EZ'\D>@?\ARS_P"N\?\`Z$*_M(3[@^E?Q;Z!_P`ARS_Z
M[Q_^A"O[2$^X/I7W7'OQ4?\`M[_VT^-X.^"I_P!N_J+7Y4_\'9G/[%O@#_L<
M5_\`2.XK]5J_*G_@[,X_8M\`?]CBO_I'<5\QPY_R,Z/^+]&?19W_`+C4]&?@
MSX+\3:Q\/?$>F^(]%N;O3=1T>\2XL[Z`E&MKA"&1E;^\,9_"OZC_`/@D+_P4
M6TW_`(*-_LO6?B)WMK?QEH833_$UA&<>1=!<B55[12@%E]#N7JIK\1_^"57[
M!,W_``4%_8R_:4\-Z6J-XN\,S>'=<\.[B%$ERJ:JKP$]A+'\OIN"'M7DW_!-
M3]N;Q)_P3)_:ZM/$;P7JZ7YQT?Q5HT@*//;;\2*5.`)HF&Y2<$%2O`8U^@9[
M@J69PJ4J=O:TMN[32=O1_F?&Y/BI8%TZD[NG4_!IVO\`UT/ZOJ*YWX4_$_1/
MC)\/=%\3^'+Z'4]"UVSCO;&[A8%)XG4,K#\#R.QR#R*Z"1Q$A8]!7Y+*,HOE
MDM3]&335T$F`IST(YK^;?_@X'_X*5/\`MK?M+KX&\*WSW/P^^'EP]I;-`VZ/
M5[_[DUQQ]Y5(\N,^@8C[]?IC_P`'"W_!3$?L=_LWCP/X7O3!\1/B/;2VL31O
M^\TJP^Y-<\<JS9,<9]=Y_@K\CO\`@D/^P/J7[4_C;Q?X\O;5QX)^%6B7FKW5
MPZ?)=WR6LCVMNN>I#J)&]%3G[PK[GA?`TZ%.69XG1+2/KM=>?1'RF?8N=:K'
M`4-WK+T_K<^7/@H#_P`+B\)GG_D,V?\`Z/2O[*XO]4OTK^-7X*C'QC\)^G]L
MV?\`Z/2O[*HO]4OTK;CQ>_1])?H8\(_PZO\`B7Y#J_(__@[C_P"3:?A+_P!C
M1<?^DC5^N%?D?_P=Q_\`)M'PE_[&BX_])&KYSAG_`)&='U?Y,]O/O]PJ>GZH
M_*;_`()=_L*0?\%%/VI[?X;S^))O"T<VEW6H_;H[,73#R0OR["Z]=W7/:OTH
M'_!HIIA_YKA?#V/AI/\`Y)KY7_X-C6V?\%1K`XS_`,4SJ7\HJ_I#2Y`0#*\#
MU/\`A7T_%>=XW"8WV6'G9<J>R>_J>!D&5X3$83VE>%W=_AZ'XR?\0B>F?]%Q
MO?\`PFD_^2:7_B$5TQ>OQOOC_P!RTG_R37[-_:AZK^9_PI#=J.Z_G7S/^M>:
M=:OX1_R/:_U?R[_GW^+_`,S^8'_@K1_P1SUS_@EV_A;4'\5VOC+PWXK>:W@N
MUL393VT\2JQC>/>X(96RK!OX6!`XS[;_`,&J7Q"U'0/V]O$_A^&:3^S-?\(W
M$MS"3\AEAN+=HY,>JAY!]'-?27_!W%XGL7^#/P>TK[3$-1?6[ZZ6WW?O#$L"
M*7QZ!F4?4U\J_P#!K5IMQ=?\%(=3GBAD>&S\&WSS.!Q&#/:J,_4L!^-?;+&5
M<7P_.KBM96>O?6R/FUAJ>'SJ%.AI&ZT^1_1;&,(.U*_W#]*2'F/\3_.E?[A^
ME?E4%;0^_9_'9^UG_P`G4_$S_L:]4_\`2R6OT?\`V//^#96/]J_]F+P1\1C\
M8VT(>,=)AU,6'_"-BX^S;QG9O^TKNQZX%?G!^UG_`,G4_$S_`+&O5/\`TLEK
M^GG_`(([2"+_`()A_!#//_%)VG3Z&OUCB/,L3@\%1GAI6;LMD^E^I^=Y!@:&
M)Q52->/,EK^)^>'_`!"'1$_\EY;G_J4O_NNC_B$-A_Z+RW_A)?\`W77[2BZ7
M%#7:J,X-?%/BG-5_R]_"/^1]7_J[E_\`S[7X_P"9^+1_X-#8?^B\M_X27_W7
M7??LK?\`!L,G[+O[2W@7XAI\9#K9\&:S;:O]A/AK[.+KR9`_E^9]I;;G&,X-
M?K6C[UR.E+6=3B;,JD'"=31Z/1?Y%0R'`0DI1IJZ]?\`,1>G?I7C/_!1[_E'
MG\=_^R>Z_P#^FZXKV>O&/^"CW_*//X[_`/9/=?\`_3=<5X^#5JT%YK\STL3_
M``9^C_(_D8TRT^WZA;P;MGGR+'NQG;EL9K]JK;_@T=TRZMTD'QNOUWJ&P?#2
M<9'_`%\5^+7A_P#Y#MC_`-?"?^ABO[/]'_X\(_\`<7_T$5^G<79IBL&J7U:7
M+>]]$]FNZ/@N&<NP^*C4]O&]K6WZGXT_\0B>F_\`1<+[_P`)I/\`Y)I/^(13
M3`1GXWW_`"?^A:3_`.2*_:&BOB_]:<T_Y^_A'_(^I7#V7_\`/M?C_F?S!_\`
M!6?_`((Q:[_P2^L_#FM#Q9;>-/"OB2Y>RCO%L393V=PJ;Q')'O<$,H8A@W\#
M9`XSZ/\`\&NGC?4/#W_!2:?2+>9EL/$'A>]CNXLG:_E-%+&V/4%2![.:^X?^
M#LCG]B;P+T./&4?_`*1W%?!'_!LC_P`I2M'_`.Q=U/\`]%K7VE'&5<;D%6KB
M7=VDNVQ\S/"4\+G5.G0T3:_$_I*!YQ22]%_WA3J;+T7_`'A7Y5>ZN??/8_D3
M_P""BW_)_OQJ_P"QXUC_`-+9:_HH_P""`'_*(?X.?]>NH_\`ITO*_G7_`."B
MW_)_OQJ_['C6/_2V6OZ*/^"`'_*(?X.?]>NH_P#ITO*_2^+?^170]8_^DGP_
M#W_(QK?]O?\`I2/L:BBBOS4^Z"BBB@`HHHH`*_.W_@XP_;_/[*/['5SX+T2\
M^S^,?BBLFE6QC?$EK8``7<WJ-RMY0/K(2/NU^@GB36;7P[HMSJ%]/%:V=E&T
M\\TK;4AC12S,Q[``$GV%?RI?\%3/VS]0_P""B/[<FO\`BBQ6YN-'-RNB^&;-
M,L5M(VV1%5_O2N6D(QG=+CM7TW"V5_6\7[2:]V&K_0\+B#'?5\,XP?OST7ZG
M'?LY_L+>.?VG/@C\4?'OANS,NB_"K3H]1U'*$M=;GRT<78LD*R2L.<*@_O"O
MH_\`X-\?V^Q^QS^V5;>'=;O?L_@?XF-#I.H>8_[JSNPQ%K<Y/``9F1C_`'9,
MG[HK]M?^"4O[!EC^Q!^PAX?\#WUG;3ZWJMN^I>)@R!A=7EP@\V-N/F5$"1#U
M$>>]?SS_`/!5[]B:Y_8&_;7\3^#X(I4\.W4O]K>'9N</8S,6C4'UC8-&?=,]
MZ^OPN;4LVG7P-3X6O=[Z:7^_4^:K9?4RZ-+&0UE]KY_\#0_K`HKXL_X(7?M\
MI^W1^Q7I4^JWJW'CCP6L>A^(`S9EN'C3$-T<\GS8QN)_OA_2OM.OS+%8:>'K
M2HU%JG8^\H5X5J<:D'=-7"BBBN<U9_,%_P`'#!/_``]E^)8[%-._](8*^>?V
M3?VKO'7[$/QNTKQSX(U";3-6LB/,@DW&VU"W;!:&9.-\;K^7!!!`(^AO^#A?
M_E+-\2\]/+T[_P!(8*]_\'_\$AY_V^?^"+_PJ^)?@*UB'Q4\+VVIV;VO`_X2
M.SAU.[58<D@"9`#L)X(^4]B/V.GC,/1RW#QQ2O":C'RU74_,ZF'JU<?6=!VE
M%MJW6S/UI_X)G_\`!2OP9_P4@^"=OK_AZ6.P\0:>JQ:[H<DH-QIDV#SCJT3$
M$HX&",@X(('TK7\@?[,_[2WQ!_8`_:(MO%/A>>ZT+Q/X>N6M[^PNHV5;A5($
MMK<Q$@E3C#*>01D$$`U_3#_P3(_X*<>"/^"D?P936M`8:9XETW;%KF@S2AI]
M.E/1@?XX6YVN!S@@X((KX3B'AZ6"E[>CK2?X>OEV9]?DV<QQ4?9U-)K?S/IN
MOGC_`(*S_P#*-;XV_P#8H7__`**-?0]?/'_!6?\`Y1K?&W_L4+__`-%&O!P/
M^\T_\2_-'K8O^!/T/YGO^":__*0KX(?]CSH__I;%7]<MO_J5^E?R-?\`!-?_
M`)2%?!#_`+'G1_\`TMBK^N6W_P!2OTK[+CS_`'BC_A_4^7X._P!WGZ_H/KSC
M]K__`)-6^)?_`&*>J_\`I))7H]><?M?_`/)JWQ+_`.Q3U7_TDDKXG#_Q(^J/
MK:GPL_CWM(?M%S''NV^8P7.,XR?2OV9\/?\`!I+'X@T&ROF^.KPF]MXY_+_X
M1/=LW*&QG[6,XSUK\:--_P"/^#_?7^=?V:_#W_D0=$_Z\(/_`$6M?J'&&;8O
M!>S^K3Y;WOHO+NO,_/\`AK+</BO:.O'FM:V_F?C8?^#0Z%5)_P"%\MQ_U*7_
M`-UUE>(?^#1758[5GTGXY:?-+CY8[OPL\:D^[I=-_P"@FOW`HKXR/%F:)W]K
M^"_R/J'P[E__`#[_`!?^9_,I^US_`,&]?[0G[*V@7FNP:7IGQ`T"Q4O-<^'9
M7FN(4'5FMG59,`9)*!L`$G%?//[%7[</C[]@CXTV?C'P/J<UK+"ZKJ.F2NQL
M]6A!^:&=!U!&<-U4X(K^NZ>'SACCT/O7\^/_``<U_L":-^SG\?-!^*/A:PBT
MS1OB4\\6J6L"!88=2B"LTB@<#SD;<1CEE<]S7T^1<1O,)_4<?%/F32??RMW/
M`S7(U@H_7,&VN7=?Y'[:_L2_M?>&_P!M[]G/PY\0_"\G^@ZS#BXMF;,NGW*G
M;+!)_M*V?J"I'!%>%_\`!<GQ3JMA^REX>\*:;J-QI$'Q3\;:/X*U.]@;9);V
M-W)(9]K=MRQ[/HY'>OSY_P"#3K]I^YT+XP>/?A%>7#MINO6(\1Z;$S?+%<PE
M(9\#U>)HR?\`KB*_7/\`;K_9&TW]MO\`9PUWP'J-[)I4UZJ76FZE$I:72[Z%
MA)!<*,C.UP,C(R"1D9KY3&8..79I[*?PIIKT?^7Z'T>$Q4L9@/:0^*UOGU^_
M]3\[/VV$\`?LR_MRWGA;5]&^-2?"GP)\*["[M=,^&^H75K#HQ6[G1KJY$,\2
MA"@P9&SEL9SUK!\>>$_&OPG_`&#OA?\`M`>()=8MO'_@KXC6\_@Z^U6]2[UJ
MZ\*W]VL4-A?7"$^=O@ER>3@=,9(KV#P)XU\?_`;XZ:SXE^/'P.^*7C?Q??\`
MA*+P->:KX$T^#7?#OB&SCG>07'E%HY8)9-Y#(XV\G@`XJM^RI^PE\0OV@M5\
M#:!XGT+Q1\/_`-G+X6ZZ_B7P[X;\574-QX@UFX5V>TMYEB!$-G;LQ*QR,[D`
M`\8V^G[:%.$74DK1M=WOS:--15]W^*WL<;IN;ER==E;;5:OT]?O/TYM\F%#G
MC%24R!/*B5?[HQ3Z^,5NA]&%87Q,\.7OB_X>ZYI>G72V-_J-A/;6URREA;R/
M&RJY`Y(!(./:MVH[N[BL+62>>1(885+R2.P544#)))Z`"J3L[H35U8Y#]GSX
M):/^SK\%O#/@G0X$ATWPU81V41"@-*5'S2-ZN[%G8]V8FNSI(W61`RD,K#((
M.012T2DY-RENP225D%%%%(84444`%%%%`!1110!\<_\`!8'PQJ?B?P3X*33=
M.O\`47AOKDNMK;O,4!C4`D*#BOS^U3X<>(H"V_0-<3'7=82C'_CM?N,R!NHS
M044]AQ0!^#&K>'-1LE8S6%["!D'?`ZX_,5SU]$T3?,K+GU%?T"36,-RI$D4<
M@/4,H-9&K_#'PUX@0K?^'M#OE/47%C%+G_OI30!_/W><%JR+P<D^M?O%XI_8
M=^$'C!'%]\.?"99\DM!8);L?^!1[37DWCG_@C7\$O%^]K32M:\/R/_%8ZG*X
M!]=LQD`^E`'Y+>#.J?6O6/!G\-?6?BS_`((7_P!D%Y/"7CEI-IRD&K6>,^WF
M1G_V2O,O%/[`GQ2^#FZ6\\-2ZK8Q];K27%XG'4[%_>@>Y04`4?"<:R*`PROI
M7VU^R+^TY/K8M?"OB6Y:6^(":;?R'F\`'^JE/_/0`<-_&,]P=WQ-X3S%.\3@
MI+$=KHPPR'T(/(/UKU3PG`MU&HWNC+@I)&Y5XF&"&4CD,"`01R"!0!^B(8$D
M#M2UYY^SI\67^)/@YH=0=1KFDE8;U0-HFR"4G4=E<`G`Z,&':O0Z`"D?[A^E
M+2/]P_2FMQ,_E6_X+>_\I6/C3_V&U_\`2>&OVJ_X-G/^45/AK_L-ZI_Z4-7X
MJ_\`!;W_`)2L?&G_`+#:_P#I/#7[5?\`!LY_RBI\-?\`8;U3_P!*&K]*XB_Y
M$E#_`+=_])9\-D?_`"-ZWI+_`-*1^@%%%%?F:/N@HP,YQS2-G:<=>U?*_P"T
M-_P6;_9W_9/^+FI^!?B!\0'T+Q/I*Q/<V?\`8&I77E"1`Z_/!;NARK`\,>M;
M4:%2M+EI1<GOHK_D9U:\*4>:I*R\]#ZIQ17E/[)'[9?P^_;?^']QXL^&NOMX
MC\/VMY)I\ER;"XL]LZ!6*[)XT?A77G&#FO5JFI3G3DX5$TUT94)QFN:+NC\N
M/^#K_P#Y,.\(?]CE!_Z2W%?G)_P;8?\`*67P5_V"]6_](9J_1O\`X.O_`/DP
M[PA_V.4'_I+<5^<G_!MA_P`I9?!7_8+U;_TAFK])RG_DG:OI,^&S3_D<T?\`
MMW\S^F*BBBOS,^["O$O^"DG_`"8!\;O^Q%UC_P!(IJ]MKQ+_`(*2?\F`?&[_
M`+$76/\`TBFKHPG\>'JOS,J_\.7H?R1Z!_R'+/\`Z[Q_^A"O[2$^X/I7\6^@
M?\ARS_Z[Q_\`H0K^TA/N#Z5]UQ[\5'_M[_VT^-X.^"I_V[^HM?E3_P`'9O\`
MR99X`_['%?\`TCN*_5:ORI_X.S?^3+/`'_8XK_Z1W%?,<.?\C*CZ_HSZ+._]
MQJ>C/(_^#090]Q^T$"`0?^$<&#_W%:Q_^#E;_@E4_A+5I?VA?`^FJNG:E*L?
MC&TMX_\`43L<)?X'\+G"2?[11N=S$;/_``:"?\?/[0/U\.?^Y6OV6^(O@72_
MB9X,U+P_K=A;ZIH^LVTEG>VDZ;X[B)U*LK#T()KV,TS*I@<]G7AMI==URK0\
MO+,##%Y/"C/SL^SNS\/?^#:7_@J6/AIXTC^`/CG4MNA:],\OA.[GD^2QO&^9
M[/)Z),<E/23(_C%?M'^T1^T%X:_9G^"7B3QYXJO19:#X9LGO;F0\,^T96-`>
MKNV%4=V8"OYD?^"JO_!/S7_^"8W[6\^EV,E\OAC4)SJOA+5U+*YA#@B/>.DT
M+X4\YX5N`PKIO^"@?_!9OQU^WM^S)\._AUJZ26`\/P>9XFN4D`7Q%?(62&4@
M=%6,!R#QYCL?X5KU,PX>IYA7I8W"/]W/67E_P^WDSBP>=3P=&>&Q7QP^'S_K
M\CSGXL>//B-_P5\_;Z>YM;:2^\3^/]36QTJQWDPZ7:@XCCS_``Q11Y9FQV=N
MIK^B#X<_L7^'?V#/^":/B?X=^'8XY(],\):E)?7VP+)JEV]JYFN'[Y9N@/10
MHZ"OE?\`X-O?^"7S?L[?"$?&;QAI@B\9^.;<+H\,R8DTG3&Y#8ZB2?ACW"!!
MW85^A_[5W_)LGQ$_[%?4_P#TEDKR>(<UC4KPP6&TIP=O5K_+8]+)LME2IRQ5
M;6<_P1_(I\%?^2Q^$_\`L,V?_H]*_LJB_P!4OTK^-3X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E>AQ]_%H^DOT.#A#^%5_P`2_4=7Y'_\'<?_`";1\)?^QHN/_21J
M_7"OR/\`^#N/_DVGX2_]C1<?^DC5\WPS_P`C.CZO\F>YGW^X5/3]4?AIX'\?
MZ]\-M=&I>&];U?P_J2QF,76FWDEK.%.,KOC(;!XR,]J[#_ALGXO*?^2J?$;C
M_J9+W_XY7UM_P;4>'M/\5?\`!3BQM=3L;/4;5O#6I,8;F%98R0(\':P(SS7]
M%D7P3\&F-2?"?ALD@?\`,-A_^)K[W/>(J6!Q7L945/1._KTV9\AE&2U<5AU5
MIU7%7>FO^:/Y'?\`ALKXO9_Y*I\1O_"DO/\`XY1_PV3\7F/'Q3^(WX>)+S_X
MY7]<G_"DO!O_`$*?AK_P60__`!-'_"DO!N,?\(GX:_\`!9#_`/$UXW^NM'_H
M&7WK_(]/_5C$?\_W^/\`F?Q[ZOXWU/XJ^,K2Z\:>*-<U#S'6.;4;V634;B&/
M/)`D?<V.N-PK^B#_`(-[_P!E#X'_``=_9^OO%_PN\8I\1-=\2A+?7-8EMOLL
M]DR886?V=LO"%)W?,3O.&R1C'SC_`,'4_P"R/X%\"_"#X??$?P]X9TG0M?GU
MQ]$O[C3[9+?[?%);O*GFA0`[*83AB,@,1GI7SE_P:Y_&O5O`_P#P4*O/"-O=
MS#1O&_AZZ2YMLYC::WVS12XZ;E`D4'TD->AF=;^TLF>)H7@E=N/>W3]4<N!A
M]0S-8>K[[E:TNJN?T5``#`XI'^X?I38'+Q@GJ1FG/]P_2ORY'WC/X[/VL_\`
MDZGXF?\`8UZI_P"EDM6_"W[97Q@\#^'K/2-%^*GQ'TC2M.B$-K967B6\M[>V
MC'1$C20*JCT``JI^UG_R=1\3/^QKU3_TLEK^DW_@D9\`/`GB7_@FO\%[[4?!
M7A._O;KPM:R37%SI%O++,Q7EF9D))]S7[)FV:T\!@Z52K3YT[*WR/S#+,NJ8
MO$3C3GRVU_'U/YS/^&]/CG_T6;XJ_P#A67__`,=K2\&_MV_'&Y\7:5&_QC^*
M;I)>0J5;Q7?D,"XX.9:_JP_X9C^&W_1/O!/_`(([7_XBA?V9?ANC!E^'_@I6
M4Y!&B6P(/J#LKYN7&.%<6OJR_#_(^@7#-=/6N_Q_S.K\/.9-'@)))**<GOP*
MNTV&%+>,*BA5'0"G5\`W?4^P"O&/^"CW_*//X[_]D]U__P!-UQ7L]>,?\%'O
M^4>?QW_[)[K_`/Z;KBM\+_'AZK\S#$_P9^C_`"/Y&-.N_L%_;S[=WDR+)C.,
MX;.*_:*T_P"#N."TMDC/P5N6*@#/_"2A>@Q_S[FOQ?TJU6^U.VA<D)-*J,1U
M`+8-?O#9?\&F/PDN[1'/Q,^(H+`$_N[/`R,_\\J_6N(9Y6E3_M%-O6UK_/9^
MA^<Y'','&3P+MM>]OEN<'_Q%VP?]$2N?_"F'_P`C4?\`$7=`#_R1*Y_#Q,O_
M`,C5RW[>W_!KNGP5^`&H>*?A!XG\2^,O$&B9N;K1M32$/>6RJ=_V<QHN95X(
M4YW`$#YL`_DOX'MM%M/'NGP^+8M830H[M8]433RD=]%%NP_EB12N\<G##DC'
M&<UY^!RG(<93=3#PO;I>5_NN=N+S+-L-45.M)*_DK??8^P/^"LO_``6C\0?\
M%0='\-Z$WA.U\'>&?#ER]^EJM\;V>[N63RP[N40`*I8!0/XCST`]*_X-;OAS
MJ7B?_@HM>Z_;P2MIGACPS=M>3A3M1IV2*)">@+?.1GJ$;TKZ4_9=_P"#</\`
M9J_:E^&6B^.O"'Q>^(7B7PQJJ"1&MWLHG5@1OBD_<%HW7HRD9!_"OTP_8G_8
M%^&7[`_PVF\-?#G0?[-@O95FO[R>5I[S4I%&`\LC<G&3A1A5R<`9->?F>>X"
MA@)Y?@HM-Z6::M?>]];G=@,HQ=7%QQN*DG;73KVVTL>U"FR]%_WA3@,4V7HO
M^\*_/->I]B]C^1/_`(*+?\G^_&K_`+'C6/\`TMEK^BC_`((`?\HA_@Y_UZZC
M_P"G2\K^=?\`X*+?\G^_&K_L>-8_]+9:_HH_X(`?\HA_@Y_UZZC_`.G2\K]+
MXM_Y%=#UC_Z2?#</?\C&M_V]_P"E(^QJ***_-3[H****`"@G%%8_COQE8?#_
M`,*ZAK6JW<5CIFE6TMW=W$I`2&*-2S,2>P`)HLVTD%TM6?F[_P`'+'[?!_9Z
M_93C^%VAWWE>*?BAN@N2CGS+/2T;]^WJ/-;$0]5,OI7Y\_\`!M]^P@?VI?VS
M$\=ZS9^=X3^%>S4\2)^[N=2))M8\]RC*93_US7UKYD_X*3_MG:A^WI^V%XM^
M(-S).-+NKDV>AVLG'V/3HB5@3'0,5^=O5Y&KZ<_X)L_\%Z[;_@F_^SA:^`M#
M^$%AK-P]Y-J&I:K+KC02ZC<2'`=D$)VA8U1`,GA<]2:_5:>4XG"9/]6PT+U9
M_%Y7_P`EI^)^>3S*A7S+VN(E^[AM\MO\S^CN&+RX=I`QSQ7YS?\`!R1^P9_P
MU#^R"GCS0K%9?%_PK\S408T_>7>FL!]JBXY8IM24#MY;X^\:^8/^(O#6/^B)
M:7_X4<G_`,CU7U/_`(.V]0UFQFMKKX&Z1<6]Q&T4D;^(I"LBL,%2/L_((KYG
M`</YOA<1#$4Z>L7W7W;GO8S.\LQ%&5&=31^3_P`CXP_X(E?M\R?L'_MJZ-?Z
MG>20^"?%X71?$*ECY<44C#RKDCUBD()/78T@[U_499WT=Y#$T;K(LB!U93D,
M",Y![U_&7\0-<TWQ'X[UG4=%TO\`L+2K^]EN++3O.\[[!"SEDA#X&X("%!(!
M.*_HO_X-V?\`@H"O[7/['UOX2UV^\_QM\,$32KSS&S)>66,6MQ[X1?*8]=T6
M3]X5Z_&N6.48YA!=E+]/\G\CS^%\P47+!R?G'^OQ^\_0RBD1@ZY!R#2U^<GV
MC/Y@O^#AG_E+-\2_^N>G?^D,%?LS_P`&Y\:O_P`$B_AAD`XFUCJ/^HM>5^,O
M_!PS_P`I9OB7_P!<]._](8*_9S_@W-_Y1%?#'_KMK'_IVO*_0^(?^1%AO^W?
M_26?$Y1_R.*_S_-'E7_!<3_@AY:?MAZ+J/Q/^&5A::?\4K"+S+NRC`BB\41J
M/NMV6Y`&%?\`C`"L>%(_#7]G;]HGXA_L#_M"6OBCPM=7_AKQ;X=N6@N[.XC:
M,2J&Q):W$1P60D892.V1@@&O[`'0.N#TK\U?^"WG_!$"P_;6T2[^(WPUL;;3
M?BMID&ZX@4B*'Q/$@XC<]!<`9"2'&[A6XP5X.'>(8P7U+':TWHF^GD_+\COS
MG)I2E];P>DUJTNOIYGT=_P`$R?\`@IYX)_X*0?!5=<T64:;XHTQ4CUW099`9
M].E(X9?[\+8.U\<]#@Y%:W_!6?\`Y1K?&W_L4+__`-%&OY@_@#\?_B+^P;^T
M%!XC\,7>H^%?%_ARY:"\M+B-HPX5L26MS"?O*2,,C=",\$`C]W=:_P""FGA3
M_@IM_P`$=OC1JVC-%I?B[2O!M['X@T"1\RV$OD-ET/5X6()5QZ8.#D4\SX>>
M#Q5/$4-:4I+SMJOP[,>79TL70G1JZ5$G\['X>_\`!-?_`)2%?!#_`+'G1_\`
MTMBK^N6W_P!2OTK^1O\`X)K\?\%"O@A_V/.C_P#I;%7]<EO_`*E?I6_'G^\4
MO\+_`#.?@_\`W>?K^@^O./VO_P#DU;XE_P#8IZK_`.DDE>CUYQ^U_P#\FK?$
MO_L4]5_]))*^)P_\2/JCZRI\+/X^=-_X_P"#_?7^=?V:_#W_`)$'0_\`KP@_
M]%K7\96F_P#'_!_OK_.O[-?A[_R(.A_]>$'_`*+6OT#C_P#Y<_\`;W_MI\;P
M=M5]5^IL4445^<GVH5^8'_!U;HUO>_\`!/WP_=2;1/9>,K5HL\DEK:Y4X_"O
MT_K\<_\`@[0^/-C9?"KX:?#6&XCDU34=5F\0W,2L-T4$,;P1DCT9Y7P?6(^A
MKW.&Z<IYG145U/*SR<88&JY=OS/AC_@W3UB?2/\`@K3\.$A)"WD&IP2#LR&P
MG)_50?PK^G,C-?S>_P#!L/\`"^X\<?\`!3BPUM(F:U\':!?W\LFTE5:5!;(#
M]?.8CZ5_2$.17I\:R3QZ\HK\V>?PI&2P3;ZR?Z#!;Q@_<3GVIRQJAR%`/L*6
MBOD#Z5!1110`51\2Z1'X@\/7UA,H:*^@DMW!&?E=2I_0U>H/-`'CG[*OQ8:^
M\.V?A'69676](A,$+RGF^CBRC`'O)&5*L.IVAOXN/8\XKY2_:+\(MX-^*-ZJ
M-)##J+#5]/EB.QH)<@2[&'(99/GS_P!-A[BMCX7_`+;#>'BNG^-HGEB4[8]7
MM8LG'_3:(#@_[29!_NK0!]*T5F^%O%^E^-]*CO\`2+^SU*RE&4GMIEE1_H03
M6E0`4444`%%%%`!1110`4444`%%%%`!1110`4C*'&",BEHH`XOXF_L^>$/BU
M"QUO1;:>Y`PEW$/)N8_<2+AOP)(]C7@/CS]C_6_AB\E[H,LWB32E^9H2@%_`
M/]U0%F&.RA6_V6-?65!&10!\F?!GQDGA'Q?IFLPRAK&5A8WY7H(9&QN8>L<@
M!.?N@R#C)KZS'3TKQ[X_?`R*^M+W7M(@;[9)&W]I6D(P-1C*X9U':91R"/O`
M;3GY2O;_``4\7_\`"=_"[0M4:59Y;FS7SI%Z/*OR2$?\#5J`.JILAQ&QR!@=
M3VIU)(F]&7U&*`]3^5[_`(+FZ=)IG_!5WXS)(.9-6AF7W5[2!P?R-?K=_P`&
MZ/[1/@/X<?\`!,7P[IFO^-?".B:C'K.I.UK?ZO;VTRJ;AB"4=@P!'/2O&O\`
M@X+_`.",'Q!^/?QT7XR?"G2?^$GDU2QBM=>T:W9$O%FA&Q)XE8CS`T852H^8
M&,$`[N/RDU;_`()^?';0;TV]W\'?B7!<)U1_#=X"/_(=?JL8X7-<KI47547%
M1OMNE;9M'YZYXC+\PJ5HTW)2O]S=_,_JJ'[8WPI(_P"2F?#W_P`*&U_^+H_X
M;%^%'_13?A[_`.%#:_\`Q=?RE_\`#"?QL/\`S2/XD?\`A.7?_P`;H_X82^-G
M_1(_B1_X3EW_`/&Z\W_4W!_]!*^Y?YG?_K/B?^@=_C_D?U9M^V-\*?\`HIGP
M]/\`W,-I_P#%U_.%_P`%]?&>D^/O^"HOC_5-#U33]8TVX@T\175C<)<0R8LH
M0<.I*G!R.#7A/_#"?QMZ?\*C^)'_`(3EW_\`&Z[OX+_\$BOVD/CKXEM=.TGX
M1^,;!;EPC7NL6$FFV<`)P6:68*,#T&3Z`UZF49/A,KJ2Q"Q">ENB_4\_,LSQ
M./IJC[%K6_5_H?LE_P`&K%E+;?\`!.C6)9$VQW'C"],9/\0$%L"?SR/PK],3
M7@7_``30_8X@_8-_9`\)_#9+J*_O=)@>?4[N($)=WDSF29U!YV[FVKGG:BU[
M[7YQF^)C7QM6M#9R=C[?+Z+I8:%.6Z2/S!_X.LM*EOOV`?#=R@S#9>,;4R'!
MXW6UP!7YC_\`!O+XVT?X<_\`!4CP=JNO:KINC:9#IFJK)=7UREO"A:RE"@NY
M"@DG`YK]]_\`@IG^Q/!^WW^QUXN^'37<.GZEJ$27>E7<L>Y+:]@;S(2W<*2"
MC$<A7;%?S<_&7_@DA^T;\#?$-U8:O\(_&5XMJQ47NE:?)J-G,,D;EEA#+@^A
MP?4"OM^&,1AZ^5U,#5FHR=]^S/D\^H5J6.AC(0;2M]Z/Z>_^&Q?A1_T4SX>_
M^%#:_P#Q='_#8OPH_P"BF_#W_P`*&U_^+K^4O_AA+XV?]$C^)'_A.7?_`,;H
M_P"&$OC9_P!$C^)'_A.7?_QNL_\`4W!_]!*^Y?YFO^LV)_Z!W^/^1_5I_P`-
MB_"C_HIOP]_\*&U_^+KQS_@H5^U3\-/$?["GQDL;#XA^![V]O/!6K006]OKE
MM+),[6<H554/DL2<`#K7\UW_``PE\;/^B1_$C_PG+O\`^-U);?L$_&^ZE6./
MX0?$J1VX"KX<NR3_`.0ZNEPAA(5(S^LK1WV73YD5.)<3*+C[!J_K_D>=>"=,
M?6/&&D6D7S2W=[#"@'JTB@?SK^SV,YC7Z5_/'_P2-_X(1_%SQW^TMX4\:?$[
MPCJ'@CP/X3U"'5I(-8C\B\U:2%M\<*0'YU4NJEF<#"YQDGC^AU/NCZ5YW&N/
MHXBM3IT9*7*G=KSM_D=G"N#J4:4Y5%;F>E^R%K\J?^#LW_DRSP!_V.*_^D=Q
M7ZK5^97_``=!_"/Q7\9/V1O`^G>$O#>N>)KZV\5K<2V^EV4EW+'']DG7<RQJ
M2!D@9/<UX?#TDLQHN3MK^C/7SF+E@JBCJ['@?_!H)_Q\_M`_7PY_[E:_;&OQ
MW_X-5O@9XV^"-S\=/^$P\(>)?"_]I_V`;3^U=.FL_M/E_P!I[]GF*-VW>F<=
M-P]:_8BMN)YQEF=5Q=UI^2,.'H2A@*<9*SU_-GS9_P`%2/\`@GQH/_!1/]EC
M6/!]\(K7Q#:YOO#NILHW:?>J#MYZ^6XRCCNK9Z@5^,O_``2)_P""(/CGXP?M
MH-_PN'P5KWAWP3\.[H7&I1ZE9200Z[<1R$1VT3,`LL3,A9V3(*#&?G%?T6XY
MI`,5E@<_Q6%P\\-3VE]Z[V_KS-L5E%#$5X5ZBUC]S]2*QL8].MDAA54BC`5%
M4`!0!@``=@*X3]J__DV7XB?]BOJ?_I+)7H-<%^U%97&J?LZ>/+2T@ENKJ[\.
M:C###&I9Y7:VD"JH')).``/6O)HV]I%ONCT9_"S^0_X*?\EC\)?]ABS_`/1Z
M5_97%_JE^E?R3?!_]A[XS6'Q9\+SS_"CXBPPPZO:.\C^'KM511.A))*8``R?
MPK^MB!MT*\$''0]17W/'5:%2I2<))[[/T/D^%*,X4ZJFFO>0^OR/_P"#N/\`
MY-H^$O\`V-%Q_P"DC5^N%?EI_P`'2_P;\6_&?]GKX7V?A'PQK_B>ZLO$<\\\
M6E6$MV\*&V90S",$@9XR:^=X<G&.94G)V5W^3/:SR,I8&HHJ[M^J/SR_X-L/
M%>E^"_\`@II87NL:GI^DV8\-ZDAN+RX2"(,1'@;F(&3Z9K^B2+]HOX>B-1_P
MG?@W.!_S&K;_`.+K^34?L)_&P'_DD7Q(/_<N7?\`\;H_X82^-G_1(_B1_P"$
MY=__`!NON\YR+#YA7]NZZCHELNGS/D,KS?$8.A[!46];]5O\C^LS_AHSX>_]
M#WX-_P#!U;?_`!=))^T;\/E1B/'?@W(&?^0U;?\`Q=?R:?\`#"7QL_Z)'\2/
M_"<N_P#XW1_PPE\;/^B1_$C_`,)R[_\`C=>2N#,-_P!!*^Y?YGH_ZS8G_H'?
MX_Y'ZJ_\'3/[9G@3XE_"3P#\-_#'BG1/$.N6FNR:UJ$6F7D=TMC''`\2"1D)
M"LQE;"YSA2<=,_)O_!M5:2S_`/!5;PQ(BDK;:+J<CG^ZOV<KG\V%>!?#O_@E
MI^T5\4]4BM-'^#/Q!9Y6"^9=:/-9P)G^]+,%11]2*_;#_@A)_P`$8-5_X)_+
MJWCWXA3V,WQ$\16(L(K&U830Z):,ZR.ADZ/,[*FXKPH3`)R37HXVK@LKRF>"
MA54I236EKN_ET./#4\3F&8QQ,H<J5OP/TEMQ^Z&.F.*<_P!P_2DBC\J-5ZX%
M$S;(7/H":_+EN??,_CM_:S_Y.I^)G_8UZI_Z62U_2C_P2*^.?@GP]_P36^"U
ME?\`C#PM8WEMX6M(YH+C58(I8F"\AE9P0?8U_/\`?M0?L2_&/6OVEOB'>6?P
MK^(5U:W?B;4IX98O#]TZ2HUW*592$P5(P01UKA?^&$_C;_T2/XD?^$Y=_P#Q
MNOV#,\OP^8X2E2E64>6SZ/I;NC\UR_%5\#7G-4G*^G5=?0_K,_X:,^'I_P"9
M[\&_^#JV_P#BZ/\`AHOX>_\`0]^#?_!U;?\`Q=?R9G]A/XV$_P#)(_B1_P"$
MY=__`!NC_AA+XV?]$C^)'_A.7?\`\;KY[_4W#?\`02ON7^9['^L^)_Z!W^/^
M1_68?VB_AZ/^9[\&_P#@ZMO_`(NI;+X_>!-3O8;:V\:^$KBXN'$<446L6[O(
MQ.`J@/DDG@`5_)=_PPE\;/\`HD?Q(_\`"<N__C=>F?L7_L6_&#PW^UY\+M0U
M#X6_$"RL;'Q9IEQ<3SZ!=1QPQI=1LSLQ3`4`$DGI6=7@_#0@Y+$IV79?YFE+
MB3$RFHN@]7Y_Y']6(.37C/\`P4>_Y1Y_'?\`[)[K_P#Z;KBO9DY4'CIVKR+_
M`(*!Z+>>)?V#OC5ING6ES?ZAJ/@36[6UMK>(RS7$KV$ZHB*.68L0`!U)KXO"
MM>V@_-'U.)3]E)>3_(_D4\/_`/(=L?\`KX3_`-#%?V?Z/_R#XA_L+_Z"*_D6
MT/\`85^-4.MV3-\)?B,JK.A8GP[=@*-PY/[NOZY]%8MI\>5*G8N0?H*^XXYK
M4YJBH-/XMOD?)\)4IPC4YU:[7ZEB:U6<8.?P[U^,'_!P!_P1)_M@:Q\=?A'H
MS"[3==>+-!M(L_:`,EKZ!!_'CF1`.>7'(;/[1U%=VJWENT;A2K\$$9!'I7Q^
M6YE5P-95J/S7='TV.P-/%TG2J_\`!7H?RM?\$M/^"IGC'_@FA\9%O;$S:SX'
MUB9%U_0)),1W*CCSXL\).@Z-T;[K<8Q_39^S3^TMX/\`VM/@YI/CKP/J]OK.
M@:Q'NCECX>%\#=%(O5)%/#*>0:_&/_@NO_P0IU'P3XQNOBO\$O#]WJ>C:S/G
M7/#6F6QDEL+ASS<6\2<M$Y(W(!E&.1\I^7Y]_P""7GQ6_:>_X)K?&!=4TSX2
M?$[6?!NJR(NO^'WT&\6.]C'_`"UC)CQ'.H)P^.>A!!X^WS7!X3-Z"QV&DHU.
MJ;M?R?GYGRN7XC$Y=7^J5TY0Z-7T_P"`?TN#FFR]%_WA7-_!_P"*EC\:?AWI
M7B73;74[*TU6W6=;?4;1[2[MR>L<L3@,CJ<@@]QW'-=#=2>6JG&?F]<5^<N+
M3Y7NC[6]U='\B_\`P45&?V_OC5_V/&L?^ELM?O;_`,$+OVE_A]X"_P""5'PD
MTG6O'7@W2-3M;:_$UI>ZS;P3P[M2NV&Y&8$9!!Y'0BOQ<_;X_8Q^+_BG]N#X
MO:GIOPN\?WVGZAXQU6XMKBWT&ZEBGC>[D975@A#*00017DO_``PK\;=N/^%1
M_$C_`,)R[_\`C=?L&/P6&S'!4:4ZJC9)]'TMW/S;"XJO@L94JQI.5VUU6[]#
M^K/_`(;%^%'_`$4WX>_^%#:__%T?\-B_"C_HIOP]_P#"AM?_`(NOY2_^&$OC
M9_T2/XD?^$Y=_P#QNC_AA+XV?]$C^)'_`(3EW_\`&Z\+_4W!_P#02ON7^9Z_
M^L^)_P"@=_C_`)']6G_#8OPH_P"BF_#W_P`*&U_^+K7\#_M"^!_B7KO]F^'O
M&7A37K_RS+]FT[58+J8(."VU&)P"1SC'-?R:?\,)?&S_`*)'\2/_``G+O_XW
M7Z`_\&U_[,GQ&^$/_!1B75O%7@/QAX;TQO"=_;B[U+2)[6'S&EMB$WNH&XA3
MQ[5PYCPMAL/AIUH5U)Q5[::_B=.#S_$5J\:4J+2;WU_R/W[+X4FORI_X.=_V
M_C\(/V?=-^#6@7HC\1?$/,VKF)L26FEQMRAYR#-*`ONL<@[U^H_BCQ'#X4\/
MWVHW"3/!86[W$@AC,DC*JDD*B@ECQP`,FOY<_P!N[P/^T)^W'^U7XL^(VJ_"
M3XF1?V]>$:?:OX>N\65FGR6\(^3^&,+GU8L>]</">!IUL7[:LTHPUU[]/\SL
MS_%U*>&]G25Y2TVZ&S_P1J_X)1-_P4Z^*'B2WUG4]6\.^#?"UBLEWJ-C'&TT
MEU*P$4"[P5^Z)')QT0>HK]%Q_P`&E/PJ(_Y*C\0?QBLQ_P"TZ^P_^".G[$47
M["'[$GA;PM<VJP^)]6@76?$4A`WM?3JK-$3Z1+MB'_7//>OJJM\UXIQCQ4_J
MM1J"T6VMNOS,LNX?PT:$?;0O+K<_)/\`XA*/A5_T5'X@_P#?JR_^-T?\0E'P
MJ_Z*C\0?^_5E_P#&Z_6RBO-_UGS7_G\_P_R.W^P\%_S[1^%'_!0G_@V>T3]F
M?]E'Q1X]^'OC#Q7XIUSPM"-0GTV_AM]D]HA_?LOEJ#N1#O\`<(PQG%?"?_!*
M;]N.\_8%_;+\,^,C)+_PCEW(-+\16XSB:PF8!V([M&VV5?=,=Z_JYU?1X-<T
MV>SNHXY[:YC:*:-UW+(C`JRD>A!(K^8/_@I1_P`$E/B-^S;^V1XR\/>"O`?B
M_P`2>#);K^T-#O-+TF>[A%K.2ZPED5ANB.Z,YY.S/>OJ^'<Y>/IU,%F$DW).
MS?GT^6Y\]G.5_5*D,3@XVLUMY?U8_IW\+:Y9^)O#ECJ.GW,-W8W\"7%O/$VY
M)HW&Y64]P0015^OSQ_X-X/C=\0M>_94;X;?$WPKXK\/ZW\.Y%M],N=8TV>U%
M_ISY,2JTBC<T3!D('1/+]Z_0UCM4G&<5\#CL*\-7E1;O9GV&'K>VI1J;7/Y@
MO^#AG_E+-\2_^N>G?^D,%?LY_P`&YO\`RB*^&/\`UVUC_P!.]Y7Y1_\`!=_]
ME#XH?$__`(*@_$/6?#GPZ\;:[I%TE@(;VPT6XN()2ME"K;71"IP01U[5^N'_
M``0#\#:Y\-/^"67PYT3Q'H^I:#K%I+JQGLK^V>WN(=VJ73KN1P&&58$9'0BO
MML_K4Y9+AX1DFUR_^DL^3RBE-9M6FUH[_FC[.ILD8DC93D!ACBG45\`?9GYN
M_P#!;C_@B-IG[;_ARX\?_#RTM],^+&F0$R1KMCA\2QJ,B*4\!9AC"2?\!;C!
M7\%/AG\4_&G[(/Q)\0V\,-WH^J3V%_X9U_2KR%XQ/!-&T,]O-&<$%2=PS]UT
M4CI7]AI&:_.;_@M9_P`$2M(_;E\)7'CKP'!9Z3\6M+A+9$8CA\1QJ/\`4S'^
M&4#A)#[*W!ROVG#G$:HKZIC=8/1/M_P/R/EL[R5U)?6<+I-;^?IY_F?AC_P3
M7_Y2%_!#_L>='_\`2V*OZY+?_4K]*_EJ_8%_8D^,7@+]OKX17>L_"[Q]IMGI
M'C?2Y+RXN-#N4AMDCO(][L^S:%`!);.,"OZE+4[H%/'2M..*L*E>E*#3]WIZ
MD<)TIPH5%-6U_0DKSC]K_P#Y-6^)?_8IZK_Z225Z/7GG[6-C<:M^S/\`$*SL
M[>:[N[SPQJ<$$,2EGE=K60*J@<DDX``]:^,H-*I&_=?F?4U/A9_'KI[!+Z`G
MH'7/L,U_7;X$_:_^%EMX)T>*3XD^`(WCLH597\06H92(UX(W\&OY8O\`AA/X
MV`<?"/XD?^$Y=_\`QND/["?QMS_R2/XD?^$Y=_\`QNOUW/<LPV9\G-64>6_9
M[V\_(_-\IQV(P#FE2<K^JV^1_5H?VQOA2!_R4SX>_P#A0VO_`,76-KW_``4$
M^!_A>"634/C'\++-8@2QF\4V28_.6OY9/^&$OC9_T2/XD?\`A.7?_P`;JWH_
M_!/;X[Z]<>3:?!SXF7$AP-J>&[LG_P!%U\__`*FX+KB?R_S/7?$V*_Y\?G_D
M?O1^UY_P<B?`#X`^&KR+P?K)^)_B949;>TT>-ULM_8R73`($]=F\^@K\"/VP
MOVM_&/[<?[0.L_$+QI<I/J^L2*D-M#E;>P@7B.WA4DD(HZ9)))))))->\_!+
M_@@7^U'\:K^!!\.;CPK9RGYKOQ%<QV*1#/WC'DR_DF:_5+_@FE_P;@^!?V4?
M$FG>,?B5JL'Q%\::>XN+2U%OLTC2Y1R'5&RTSJ<$.^`.R`@&NRC5R?)8.5.?
MM*C7>[]--$<]2GF>:24*L>2'I_3;-?\`X-Q_^"=^H_L?_LS7WC3Q78R6/C+X
MFO%=-;2KMET_3XP?L\3CJ'8O)(P]'0'E37Z/CI]*;!`((E0=%Z4^OSO'8VIB
MZ\L15WE^'9?<?:8/"PPU%48;(****Y3H"BBB@`HHHH`X#]HOX5R?%#P%(MDJ
M#6=+8W5@Q./,<##1$]A(N5SV)5OX:^)/$\HFB9BCHPRK*Z[60CAE([$'(([$
M&OT9<90@9YXXKYC_`&R_V;[EGNO%_AVV:;>-^K64:Y9\#'VB,#JP``=1R0-P
M&<[@#Y&C\:ZQ\.M;;4=`U74-&OLC?-:3-$90.@<`X<>S`BO0_!O_``5:\<^`
MT6'Q!INE>*;=``7_`./.Y(]2R@H3_P!LQ7E'BQ@X9E(96Y!!R#7F?B_HW^?6
M@#[^\#?\%D?A7K;QQ:]#K_ABXQAFGMA<6X^C1DL?Q05[)X(_;>^$GQ%"?V3\
M0?#$[R8`CEO5MY,GMLDVM^E?B5XLZL,G!'/-<@G$AQ@<]J`/Z*]+\1Z?KENL
MME?6EY$_W7@F616^A!P:N!P1WK^>3P[XAU#0V#V5]>6;CHT$[1L/Q4BO0/#?
M[3?Q(\/*HL?'_C6U1?X(];N0O_?._'Z4`?NV&ST!I:_%G1?V[OC#IZ!4^(GB
M5U7IYMQYO_H0-=-8_P#!1?XTQ(`/'>H$#GY[:V<_3F.@#]@**^%?^";7[7/Q
M$^.WQSO=(\5>(Y=7TZ'2);E8FM+>+$BR1*&RB*>`QXS7W50`4444`%%%%`!1
M110`4444`!&:Q_!'@>Q^'^D26&FH8K1[FXNA&3D1M-*TK!?1=SG`[#BM9Y%C
M(R<9Z5E^#_'.D^/]/GN]&O8K^VMKNXL)9(P=J3P2M#-'R!RDB.I]U-.SM<+F
MM0>1112`0J">@)%!4$Y(!-+118$)L&>@H\M?04M%`[B;!Z#\J"@(Q@&EHI6$
M(%`Z`>E+110DEL`$9%-$8`Z#&.G:G44-)[@)L'H*/+7T%+13'<3RU]!1L'H/
MRI:*/4+C3&,?=7\J<!@444K(+A2%<]<9I:*+"L-\I?[J_E3J**86"BBB@`I"
M`>P-+10#0FP>@I0`HP,`444@"D**QY`/X4M%,!-@]!1Y:^@I:*-1W$\M?04;
M!Z#\J6B@5QIC&1@#BE"!6)`'-+10&H4$9%%%`#1&!C@8'M2[!Z"EHI+0!-@S
MT%&P>@I:0L!3N%P*`]A08U/\(_*ESFB@$P`P.*1EW#!`(]Z6B@!OE*.<#-*J
M[1VI:*'KN`4444)@-,8;.0.:41@#&!2T4!=B*@4D@`$T$;AS2T4/4$-$:C^%
M?RI=@'84M%+Y@)L`["C8/04M%/4=Q-@ST%&P9S@?E2T4"8FT>@I#&.>!D^U.
MHH!:"*@3H`/H*6BBBW8`HHHH`*:(5!S@<^U.HH`;Y2[@<#(]J<1GTHHI"2L)
ML'H/RH"@'(`I:*=AA1110`4A7=U`/UI:*6C`;Y8]!^5.`P.***+"L%(5![`T
MM%,;5Q-@]!^5&P>@I:*`$V`=A1M`["EHH`:8PPY`/U&:41JIR`,^N*6BBP:+
M0****`"BBB@`HHHH`****`"D==P-+10!\D?M@?L'3:\;OQ)X%M_])D+37FC+
MA5F/4O!GA6/4IG#=1@DAO@/QS:S6-U/;W$,MO<0.T<L,L;1R1,."K*>5([@\
MBOVSKQ;]J']A[P=^TS9/<7L3:1X@5=L.JV:`2GT65?NR+['!]&%`'XP>+.&-
M<<O^L/UKZ>_:R_8`^(G[.YN;NZTN36]`A)(U73D:2%5]9%QNB_X%QZ$U\PH<
MR-]:`-&Q^Y6I9]*R['[E:EGTH`T[/^M:L'W1]*RK/^M:L'W1]*`/KO\`X(]_
M\G,:C_V`)_\`T=!7Z8U^9W_!'O\`Y.8U'_L`3_\`HZ"OTQH`****`"BBB@`H
MHHH`*;)((U))`P,]:Y3XK?'#PM\$-&;4?%>O:5H-ET22\N%C,S8SM1?O.WLH
M)/I7P7^V+_P6BNIK&YTCX5:9)9EU,9\0:K#AU[9@MFYSZ/+C'_/,UVX/+Z^)
MDHTH_/H9U*L8?$>R?\%5/^"DFD_L8_"NZTC1[N"]^(VMVKKIMHAW_P!FHP*_
M:YL?=4<[%/+L..`Q'JO_``3X^%EY\'?V.OA[HFI^<=731HKS4VE'[Q[RXS<7
M!8]V\V1\GO7XW_L>_`O5OVW/VX=`L-9N+S65N+W^V_$5[=.99);:!U=]['KO
M8I$!V\P8&!7[[0J%B0*`%"@`#H*]+.,)3P5.&$@[R?O2?X+]3GP\W4FZC]%^
MHZBBBO`.PJZOJL.BV$]W<S1P6MK$TLLCG"QJH)+$]@`#7SS_`,/=/V:/^BX?
M#OG_`*C$5>Q_'7_DC7BW_L#7?_HF2OR=_P"#;/\`8G^$G[17[$?B#6_'7P[\
M(^+-6M_%=Q:17>JZ;'<S)$MO;L$#,#A068X]Z]7`X+#U,+4Q.(O:+2LK=;]_
M0\[$XBJJ\*%*UVF];]+=O4_2[X4?M_\`P3^-NKQ:?X6^+7P\US4)SMBL[;7K
M9KF4_P"S%O#G\!7L`D5NC`Y]Z_./_@JI_P`$?OV;-)_8[\?>-;+PGH?PVU[P
MGH\^IZ=K&CG["%N8T+11/&#Y;B1PL>-N[YQM(.*ZW_@WB^/?B_X__P#!.?0;
M[QG>76IWNB:I=Z19WUTQ::\M82OEEFSEBF]H\GDB,9Y%.M@:+PCQ>'D^5.S3
M2ZJZM9ZCIXJI&O\`5ZR5VKIKUMJGJ?>%%&:*\D]!GGWQ1_:>\"?!+QAX=T'Q
M;XMT3P_J_BZ8V^BV=]<K%-JD@9$*0J>7;=)&,#NZ^M>@1MN0$]Z_)_\`X+W?
M\I%?V(O^QJE_]+]+K]7X_N"N_$X-4J%*LG\:;]+.QQX?$NI6J4VOA:7X)_J5
M];U>W\/Z-=W]W-';6EC"]Q-+(<)$B*69B>P`!)^E<K\"OV@_!G[2G@V3Q#X$
M\3Z-XMT2.Y:T:^TRX6>%9E"LT98<;@&4D?[0H_:/X_9X\>_]B[J'_I-)7P3_
M`,&K'_*-+5/^QVU#_P!)K.E2PBEA9XB^L6E;UO\`Y!4Q+CB8T+;IO[K?YGZ5
M4445PG8%9GC'QEI7P_\`#&H:SK>HV>DZ5I=N]W>7=U*L4-M$BEFD=F(`4`$D
MGH*T9I/*B9O[HS7Y@?\`!>+]H?7_`(]^.O`?[(?PTN"WBSXHW4,OB*6(%AIV
MGAR563'16V/(_P#TSB]'KLP&$>)KJE>RZOLENSFQ>)5"DYO5[)=V]D?H3\"_
MVCO`W[2?A>?6_`GBS0?%ND6\YM9+O3+M)XXY0`6C8J>&`*G![$>M=QUK\;/V
M?]";_@A%_P`%4+'X<RZC>'X&_'2T@32[V]DREEJ$86,,[G"AED<JW^Q<1$_=
MK]DHSE!]*TS+!1P\XNG+FA)7B^_?YID8/$NK%J:M*+LU_71]!:***\\[#,\7
M^*K+P1X=OM6U.[@L--TRW>ZN[F8[8[>)%+.['H%"@DGMBO`O^'NO[-&!_P`7
MP^'7/_49BKM_V[?^3,?BS_V)NK?^DDE?GC_P;S_L+_!W]H#_`()V6/B#QK\-
M?!GBC7&UZ_MS?:EID5Q.T:,FU2S`G`R<5ZV$P>&EA)XK$MVBTK*W5>9YV(KU
M57C0I6U3=W?I;MZGZ#?"C]O[X)_&W6(]/\+?%KX>:YJ$[;8K.UUZV:ZD/^S%
MO#G\%KV`2*>C`_C7YQ?\%6/^"/\`^S9I'['/C[QM9>$]#^&NO^$M(GU/3=8T
M<_80+F--T43Q@^6XDD"Q_=W?.-I!Q78_\&\WQX\8_'__`()R^']0\:75WJ=Y
MH^IW>DV5_=,6FO+6$CRV9B<N5+-'N/41C/-*O@:+PKQ>';Y4[--+JKJUGJ%+
M%U%7^KUDKM737K;KJ?=M%%*.M>4CT6>9?'S]KSX;_LO'3C\0O&_AWP<NK>9]
MB.JW2VXNC'C?LW'G;N7./45V7P^^(>B?%3P;IOB#P[JVGZWHNKPBXL[ZRF66
M"ZC/1T8$@@U^37_!SSX)M?B5\7?V8O#EZ\L5GK_B"ZTV=XR`Z1S3V4;%<]P&
M.*ZW_@@U\9]<_9=^./Q#_8Z^(=RRZUX#O;C4?"LDIP+VR<^:Z1YZJ5=;A0.T
MLG]VO?EDZEET<73?O:MKR3M=>AY"S)K&/#S7NZ)/S:O9^NMC]4B0!D\`5P_Q
MT_:/\#?LU>%8=<\>>*]"\)Z1<3BUBN]3NTMXY9B&8(I8\MA6./0$UVTW,3?0
MU^&'_!53Q=J7_!6#]LCQ[X3T"]G_`.%4_LR^%]4U;4KNV;]U=:DD+$KN'RDM
M-&(E_P!F&8CK7'E6`6*J\LW:*U;[=OFV=./Q?U>G>*O)Z)?UT2/VD^"_QP\*
M?M"^"(/$O@KQ#I7B?0+EWBBO].G$\$CHVUE##@D$8-=;7P%_P;0_\HIO"W_8
M9U3_`-*GK[]KGQ^&6'Q$Z"=U%M?<;82LZU"%5JW,D_O0444CL$4D]JXWL=!A
M?$KXD:)\)/!>H>(O$>K6&AZ'I4)GO+^]F6*WM8P0"SLQ``Y[UF?!'X[^$OVB
M?!47B/P5XET;Q5H<TCPK>Z;<+/"9$(#KN4D9!ZBOS:_X+4?%[6/VY_VIOAW^
MQMX"NI(SK-[%K'CF\MSD6-H@\Q(W(XPJ!I2#U;R!WKG?V'-3F_X(R_\`!577
M_P!GK5+BZ'PC^,)74O!-W=R%DM;MN(XBYX+'#6[=RZPGC=7O0R>^%]IS?O&N
M91[Q3M?UZ^AY4\Q<:W+;W$^5O^]V].GJ?KQ13()!*@;UI]>$>JPI&=4ZD#ZF
MEKYV_P""H_[<EE_P3W_9#UWXA3017NJHZ:=HEG(2%O+^8-Y:G!^ZJJ\C#NL;
M8P>:UH49UJD:5-7;T1G5J1IP=26RU/6OC#\??!/P`\+MK/C7Q;X<\)Z8N0+G
M5=0BM$<@9VJ78;F]AD^U?.%U_P`%W/V4[/5S9/\`&'0C*&V[TL[MXL_]=!$5
MQ[YQ7R__`,$Y?^"3$W[;>E:;^T'^U;J&J?$'Q/XQB74]'\.WMPZ:;I=F_P`T
M)>%<##*0RQ#"*K#*L<X_06V_83^#%IX>&DQ?"GX=KIP3RO(_X1RSVE?3/EY_
M6O4J4,!AY>RJ2E.2WY;)7\KW;M\CAIU<55CSP2BGM>[;];6L;GP*_:@^'G[2
MWA]M3\!^-?#/BVTCQYK:7J,5PT!/02*IW(?9@#7>U\6>$O\`@AK\(OA'^U_H
M7Q;^'M[XH^'5QI6Y[G0]`OOL^FZC(2"`ZL&98CSNB4A&XX7!S]I@8KS\7&@I
MKZO)M/NK-/MV9UT)U6K5DD_)A3+AS'"S#.1Z4^FSG$1KFM<W9\[ZG_P5B_9P
MT74KBSO/C5\/;>ZM)6@FB?5X@T;J=K*1V((-0?\`#W;]F?\`Z+A\.O\`P<15
M^='_``0`_9*^&?[2WC7]HN?Q_P"!?"_B^72O%RI9OJUA'=-;J\ER6"EAP"5'
M3TK])Q_P2H_9P_Z(E\-?_!%!_P#$U[^.P&7X6LZ$^=M6VY>U^IY.&Q&*Q%-5
M8**3OWZ.QZ!\`/VI?A_^U%I6HW_P_P#&&@>,++2IA;W<VE72W"6\A&X(Q!X)
M'->@UPGP._9F\`_LTZ=?V7@'PCH'A&SU.59[J#2K)+:.>11M#,%&"0.,UW=>
M)6=/G?LK\O2YZD.;E]^U_(*X'X]_M->!/V8M$LM3\?>+-"\(:=J$_P!FMKC5
M+I;>.>7:6V*6X)V@G'M7?5^4?_!V?_R:+\-/^QN/_I)+75EN$6)Q,*$G92.;
M'8ET*$JR5['ZKVLQG4D]/IBDU"[6QM'F=E1(U+,QZ*`,DT67^K/UJAXX_P"1
M0U/_`*]I/_0#7$E=V.E2O&YR_P`"?VE_`W[2VD7VH>`_%>A^+;'3+HV5W<:9
M<K/';S!0WEL5Z-M*G'O7>U^5G_!J9_R:]\5O^QYD_P#22"OU3KMS/!K"XJ>'
MB[J/7Y)G/@L0Z]"-5JUPKQOXT_M\_![]G+QF/#WCSXE>$?"FM-;I=BRU*_2W
MF,3DA7VMSM)5AGV->R5Y-\7?V%OA!\?O%YU_QO\`#GP?XKUKR$MA>ZGID=Q,
ML2%BJ;F!X!9L#WKFH*CS_O[\OE:_XFM;VG+^ZM?SO;\#B/\`A[K^S/\`]%P^
M'7_@YBH;_@KI^S3T'QP^'0/_`&&(C7YY_P#!R=^QC\*?V=/V4?`6J>!/A]X2
M\)ZA>^-H+*XN=+TR*VDG@:SNW,;,HR5W(IQZ@5^A/@W_`()8_LZ7?A#2I9O@
MM\.))9+2)G=M#A9F)09))'6O9J8/+84(5WS^]?3W>EO\SS:>(Q4J\Z/N^[;O
MU/9_@O\`&_PG^T-X$A\3>"O$&E^)]`N)9(8K_3YA-!(R-M<!AP2#P?>NLKE_
MA!\%O"OP"\%Q^'/!F@:5X:T*&5YH[#3K=;>WC=SER$7@$GD^YKJ*\2?)S/V>
MW2^YZL;V][<*X&U_:<\!7GQXG^&<?B_07\>VT'VJ70!<K]O2'8)-YCZ@;&5L
M^A%=]7Y.^#/^5K_Q/_V*`_\`35;5V8'"*O[2[MRQ<ONM_F<V*Q+I.%E?FDE]
MY^L5%%%<!UA5'7_$=CX9TB>_U"^L]/LK13)/<7,RQ10H.I9F(`'N33/%/B6U
M\'^'[S4[^9+>QT^WDN;B9SA8HT4LS'V`!/X5^-OP;T;QM_P<7_M.>)]=\5:Y
MK/AC]F?P%J/V6PT+3YC;MK4HPR*[=Y"FUY&(.P.JK@G=7?@,#[=2JU)<M.&[
M_))=6SCQ.+]DU"*O*6R_7R1]\?$#_@M?^S!\,]7DL=2^,OA.>YB;8W]G/)J,
M8/\`OVZ2*?P-=I^S[_P4L^!O[4>KQZ?X(^*/A'6=3DQLT_[6+>\E_P!V&7;(
MWX*<4_X2_P#!-;X#_!CPU#IOAWX4>!;2WB0)YD^CPW5Q(!W>68-(Q/<LQ->1
M_M@?\$)O@)^U5:Q7-EX?C^&_BFVF2:#7/"D4=A.N&R0T:CRGR.A*[@>0>QW4
M<L;Y;SCYNS_!?YLSE]=BN:T7Y:K\?^`?9ZR*_P!U@<>AI:Y[X5_#Z/X6?#_2
M/#\6IZQK$>CV<5FM[JMS]IO;H(N`\TI`WN>[8&370UY35FTCO3NKA03@45D>
M/_&VE_#?P1J^OZU>P:=I&B6<M]>W4QQ';PQH7=V/H%4G\*(IMV0_4XWXP_M<
M_#;X#>,=$\/^+_'?A?PUK7B,@:98ZA?)#/>DN$&Q2<D%B!GUKT=)%D^ZRMCT
M.:_!OPY^QWXM_P""\T_Q\_:"OY-1TZ.T0Z1\+[-I/+5GMG\T(W/(V`(Q''FW
M#M_!7Z)_\$-?V]9OVV?V1;>T\0S,OQ#^'A30/$<,_%Q(\8*Q7+@\YD53NX'[
MQ)*]K'Y1&A0]I3E>46E-?RMJ_P!W3U/*PF8NM4Y91M&7POO;?_/T/M.BBBO$
M/5$8X4FN`^(W[3O@/X2>/_#_`(3\2>+]!T3Q+XK81Z/IUY<K%<:D^X)B)#RQ
MW$#CN17?R?ZMOI7Y,_\`!:'_`)3(?L;?]A5/_3A#7?EF#6*KNE)VT;^Y7./'
M8ET*?M$KZI?>TOU/UF7.T9ZXI:**X#L"BB@]*`,KQ?XTTGP'H%SJVLZII^D:
M58(9+J\O+A((+=!U9W<A5`]20*^6O$G_``7-_97\+ZZ^GW/QC\.2SH^PO:0W
M-W!G/_/2*-D/U#8KXM_X.*_'5QXF_;)_9[^%WC'6]0\/_!KQ!<0WNNS1S&&&
M=S>"*7S&Z?NXMI&<[?.)K]&OA7^P'\!?"?PUT_2_#WPP^'CZ%+:H(F71K:Z%
MU&RC#&5U9I-P.=Q8YSG->U]2P]'#TZ^(YFYW:4;))+N[/4\SZU6JU9TZ%ERV
M3O>_?96T.P^`'[4_P[_:B\-'5?A]XU\-^+[*,[9FTR]CF>W/82(#OC.,<,`:
M]"KYP_9V_P""4?P4_95_:*UKXG>!?#,F@^(-:M_LQMX+N1;"S4_?\F`':N\X
M)SD#'RA>:^CP<UYF(5!3_P!G;<?/?\#NHNHX?O59^04445@:A1110`4444`%
M%%%`!1110`DB"5"K#(;@U\^?'_\`X)B_"7]H&2>[NM"_L#6)R6;4-'(MI&8_
MQ.F#&Y]25S[U]"44`?EW\7?^"'OC/PK++/X-\2:3XEM>66"\4V-R!Z9RR,??
M*_05\^^.OV,OBG\*6D_MKP-XA@BC/,\-JUS"?H\>Y?UK]QL9I"H/84`?@%%;
MO;2E)$DCD4X*LI#+]1VK2M^1C@\=J_=3Q)\._#_C)"NKZ'H^JJ1@B[LXY\_]
M]`UQ&L_L7?"C7)-T_P`._".?^F6FQP_^@`4`?#?_``1_?R_VE]2]M`GZ\?\`
M+:"OTN>["XX))K\@?^#C+0T_8A^'?POUGX0W.I_#C5-;U>\L[Z[\/7\]C+=0
MB%&$;%'!*[@#CID"OSA\$?MG_&#7G_TWXK_$RY$@`8/XGO2&^H\VOJ,MX6J8
MS#+$J:2=]->AX]?.(4L0\.XNZ_RN?U-_;5`YX^IJI?\`BJPTNW:6YNK>WC3E
MGEE1%4>N2:_G`\*_%3Q5XDVG4_$_B/4=W!^U:G/-GIUW.?05ZQ\/M%L]4NDD
MN;.VN'SG=+$KM^9%:SX4=/XJGX?\$ZH8Q2U2/VSU_P#:X^&7AF0I>>//"<<H
M./+75(7D_P"^58G/MBLA?VU?!NJ$+HD/B7Q&Y^Z-/T:XV-]))%2/'ONQ7Y^?
M!ZVCM3$L4:1JN``BA0/RKZG^#G+P_2O*Q6`I8?75_,Z8S;5SO/&/[67B6"W9
M])\`M;X!PVNZM%;L#Z[+<3Y^A9<^U>!?%?\`:9^)VOP212^*H-$@;/[K0;%;
M9@/0RRM*YQZH4_"O6_BF!ODX'>OG?XD?ZR7ZFM<OITVU[J^Z_P"9-0^?OB7;
M&]UF?4;N6YO]1G!$EY>7#W-PX]#(Y+$>V<5XEX]E6%9&;(49).*]P^)$@C20
ML54`$DDX`XKWG_@F=_P3Y?XF>)-/^*?C33V30=/F6?P_IURN#J,JD%;R13_R
MR4\QJ?O$;L8"Y^K>,IX6C[6>RV]>QQRIN<M#VO\`X)%?L1R_LR?!>?Q!K]H;
M?QKXU$5S>Q2+\^G6R@F"U]F&YG<?WGQSM!KZ_48`%(D:H3A0/H*=7Y]B<3/$
M576GNST*<%"*B@HHHK%%G)?'7_DC?BW_`+`UU_Z)DK\2O^"$?[`_Q)_:B_9+
MUK7_``A^T=X_^$6G6OB2>S?2-#@\RWGD$$#&<GSD^8A@.G117[=?&6QGU7X5
M^);2VB>>YNM*N(HHT&6D=HG"J/<D@5\.?\&W7[/?CC]FK]B?Q#H7C[PKK7A+
M6+CQ5<7D5GJ=N8)9(6M[=0X![$JPS[5[N6XMT,NK.#7-S1WL^]]&>1B\/[3%
MTFUI:7==NUC/U/\`X-[8OC-JMG)\:/VA_C'\6-/LY1*NG7M]]GMF([8+2%0?
M]D@X)P17WI\&?@]X<^`'POT;P=X2TFTT/P[H$'V:RLK9=L<*9+'W)+$L2<DD
MDDDDUTR\@4M>;B<?B*\5"K*Z6RV2^2T.ZAA*5%MP6KZ]?O"BBC/-<9TVN?D#
M_P`''O@V;XB_MF?L@Z!;ZM?Z#/K>M7EC'J5BVRYL&DN],031'LZ$[@?4"O=T
M_P""'?C!E!_X:_\`VC!_W&#_`/%5S7_!9W]G/Q[\:OVZ_P!DO7/"7A'7?$.C
M^#/$4EWKEY96K2PZ9$;S3G#RL.%&V*0_1#7Z4V[!H5([BOH\1F-2C@L/&A);
M2OHG]I^3MH>)1P,*F)K3JK[2MJU]E=F?FS\8_P#@BMXM\,?"'Q5J<G[6G[0F
MH)IVCW=RUK<:ONBN0D+L8W&[E6Q@CT-)_P`&K9!_X)J:J>@;QOJ''I_HUG7W
M]\>M*N==^!GC2QLX)+F[O-"OH((4&6E=K=U50.Y)('XU\8?\&XOP!\:_LW?L
M":CX>\>^&-9\):X_BZ]O%LM3MS!,T+06JK(%/\)*,`?]DU#Q]2OEU2-:2OS1
MMLN_:P+"PHX^FZ:=N67=]NY]]T445\^>V>=?M3_M'^'_`-E+X!^+/'OB:7R=
M(\+Z?)=R`,`]PX7]W"GJ[N51?=A]:_%K_@D;_P`%!?@KX9_:4^*'[1'Q^\?6
MNG_$[QE?/:Z38-I]U<_V79D`LR-'&R@$".%1G(2$_P!ZOJK_`(+9_!OXQ_M_
M?M(_#;X#^$O"GB:Q^%KZA;ZAXJ\4FV9=.9B2=N_HPAB#,!T:1U'5:^\OA]^Q
MY\,/A]X*TS0K'P#X0%EI%M%9P>;I%O(^R-`B[F*$L<#DDY)YKZ+#U,/A,%:I
M=SJ[V:344]$WKN^G8\6M&M7Q-X62I]T[-OKTV1^8_P#P68_X*%_LG?\`!0?]
MCS4-"T?XFVA\<>&Y?[7\-2G2KU";E1AH-YB`594RO)`#;">E?5O_``0I_P""
M@8_;M_8[T[^V+M9_'?@=$T;7PS?O+DJ,0W1]?-C`)/\`?5Z^HV_9K^'3=?`/
M@K_P1VW_`,17YH^)/V4/B/\`\$W?^"REO\1_A%X&\0>(/@_\5E,?BK3]"LC)
M%I!ED'G-L3A0DNV=,`?*TB#`JJ57"XK"RP<+Q<?>CS-/7K&]EOOZDRA7H8E8
MF;33]V5D_D^NWY'ZR45':OYD"L2<L._6I*^:N>XSR;]NW_DS+XL_]B;JW_I)
M)7Y'_P#!%W_@GY\5/VB_V%;?Q+X-_:9^(GPMTY]7OK>+0M(@+6:2H5S)D3*<
MN2,X7BOU[_;,T"]\6_LI_$K2=+M9[_4]4\+:E:6EK"I:2XEDMG5$4=R20!]:
M^9?^#>[X'>+_`-GO_@GG8^&O'7AG5O"^O1Z]?W+6.I6YAF6-V78^T]C@U]!@
ML7*AEM7D:YN=;V>EGT9Y.)P_M,=#F3MRO9VUT/SP_96_9O?]J/\`;Q\0_`7]
ML?XE_%75/&'AZZ\W0-,N?$#G2?$"J"WREPS`O'^\385+*6&59<']T_A!\+?#
M_P`$_AIH_A3PKI-IH7A[0K<6MC8VR[8X$!/`]22223R223R:^,_^"U7_``3(
MO/VP?AK9?$'X>YTKXS?#@B_T&\M#Y5QJ*1OYGV7>.0X(WQ'L_'`<FO8O^"9W
M[0?Q&^._[.6F2?%GP+XC\"^/]%VV.K0:E9M;1ZBP'RW<.>"KC[RC[K;ATP3>
M:XAXO#PQ-.5DM'#16?=+JG^!.`H_5ZLJ4HW;U4M[KLWW1]'4HZT@H)P*^>/8
M:Z'Y-?\`!QE_R=%^R'_V.3_^E=A71_\`!?;]GS7?A%XD\`_M:_#N`Q^,/A+>
MP)K0C!_TW3B^%9\<E5+M&W_3.9NRUJ?\%UOV;?'_`,>OVB/V8]1\&>$->\36
M/A3Q0UYJ\]A:M*FGPFYLF#R$?=&$<_\``37Z'?$#P+I'Q0^'VK^'=<L8;[1]
M=LI-/O;>505GAE0HZ'V*L17TD<P5"AA*BU24U)>3>J^:/"^J2K5<1%Z7Y;/S
M2T9\1?M\_P#!730?AM_P2ST[XL^"+Q&UWXHZ>+'PK"KAIK>]E0I*Q`YW6V'R
M/[\:CO7%?LM?L&O^P_\`\$1OBG'K<!'CSQQX/U37O$DTHS,DLEG(8[=B>3Y2
M'!S_`!O(>]?._P"PK_P10^(GAO\`X*00>'OB%#K-_P#`OX,:M<:]X7DO07L-
M5EF='@2)3D$[EC>5<8S"0?O5^KO[=/A/4/&?[&GQ1T31;&XU+5=5\*ZE9VEI
M;1EY;B:2VD5$4#J22!5XNIA\(X87"RNI24I/RO[J^2U?F&'C5KJ5>O&S2:2\
M[:OYO;R/E_\`X-H?^44WA;_L,ZI_Z5/7W[7Q/_P0#^"_BW]GW_@G#X>\,>-O
M#NK>%_$%KJNH2RV&H0&&>-'N&9&*GL1R*^V!R*\G.9*6.JRB[KF?YGH9:FL)
M24E9\J_(*\B_;D_:WT/]B#]F;Q3\1]?\N2WT&T+6MLS[6OKI_EA@'N[D#/89
M/:O6KEBENY'4#UK\L/\`@JY\`?BW_P`%,?V\_AO\'X/"?BK1O@;X6NDOO$'B
M*2V>*RU"8C?)L<\,4A'E1G_GI*_;FHRNA3K8A*J[05W+T71>;V*QU6I"B_9*
M\GHO5GSO_P`$5OV^/@1\"?$'Q'^,OQO^)%K'\8OB5J,@FC?3;N8Z?:;][!62
M-E'F28.T$X2*,>HKL/\`@MO^WI^S!^W5^S/:W7@OXFVW_"S_``%?+J_AN1-,
MO(9)VW*);?S&B`7<H5P20-\*=!FOUH\/_LJ_#7P_I5O96_P^\%1VUI$L,*_V
M+;':BC:!RGH!5F[_`&:_AX\)"^`_!BD]"-$M@?\`T"O5><8;ZTL6H2YEM[RM
M9*UK<NUM+'G1RW$>P^KN4;/R=[[WO?>YX7_P1X_;WMO^"@7[&WA[Q)=3Q'Q=
MHB#2/$D(/S+>1*`9<=EE3;(.P+$?PU]6U^3_`,(?V5?B9_P2^_X+'ZS>_#[P
M1XCU_P"`?Q<"-J)TFS::VT"65B07"\*()]Q&!Q!*1VK]7+1B\()).?6O/S;#
MTH5O:8?X))->5]T^UF=^7U*LJ7+67O1T?GY_,DK\N?\`@ZY\%ZIKG[#?@C6;
M2*6XTSP[XRAEU%$!(C62UN(TD;T`?"9]91ZU^HU<;\??@CX>_:0^$VM^!_%F
MG1:KX=\16K6E];2<;D/(93U5U8!E8<@J#6&78Q87%4Z[V3_X?\"L=0]O0E1O
MN9G[)OQ.T3XO?LV>`?$/AR:*XT75_#]E<6CQD;54PJ-F.Q4@J1V*D=J]%!S7
MY.?"_P#9R_:N_P""+FOW^E_##1T_:#^!EQ<R7-MH0NOL^L:+N)9MBD'!SU$8
M=7.6*(2:]6L_^"\>H06?D:A^RO\`M,P:TOR-;0^&?-M]_/'G%E.,XYV5UU\I
MJ3FYX5J<'LTU?YIM-,YZ681C'EQ"<9+R?X-71^AM%?FOX,^*G[:_[>OQZ\,Z
MKI/A]OV:/A7H-V+J[_MG9>:KKB=T>W9<D%3@*5C52=VYB`*_2*SCDC4B1MYP
M!GU]ZX<7A70:C*2;>Z3O;UMI^)V4,0JMVHM+S5K^A-39_P#5&G5'=.(X&8YP
M/2N5&S/P5_X(Y_L(ZW^V/\0/CW<Z3\9?B3\*TT/Q68I8O"U[]G34#)+<$-+R
M,E=I`^IK[H'_``0Y\8?]'@?M&?\`@X/_`,57RA_P37\6_M!?\$U?&_QB1OV6
M_BEXWMO'/B-M0MKBSA-LB1QO,%/*-N#"0$8QTKZO'_!73X^_]&1_&/\`\"!_
M\9K[;-*N.EB92PTH\CM;6'9=]=SY?!0PD:*C74E*[_G[OMH?6/['O[-^H?LL
M?!^'PIJ7CWQ9\1[B&ZFN?[9\13^??.)&R(RV?NKV^M>JC@5\Z_L(_M>^/?VI
MKCQ(OC?X)>,O@_\`V,L!M/[>E\S^T_,,F_R_D7[FQ<_[XKZ*KX_$JHJK]K\7
M6S3_`"T/H\/*G*FG3VZ;_KJ%?E)_P=G1NW[(7PV<(QCC\7'<W9<VDV/Y'\J_
M5NOG7_@J#^P;9?\`!1/]E#6OA_-=0Z;J;.FH:-?R@LEE>Q;MC.!R496=&QSM
M<XR0*Z\HQ$*&,IU:FB3U,,RHRJX6=..[1[YX?U&+5M,BN8'62"X198W!R'5A
MD$>V*J_$&Y2T\$ZK)(P1$M)69CT4!&)-?F%^S/\`\%$/VB?^"?\`X#TWX:_'
M7]GKXE^,X_#,":?8>*/!MM_:OV^WC&V,NH^5F"@#=O4D`;E!R2?M,?\`!1+]
MHG]O_P``:E\-/@7^SS\2_!2>*(WT^_\`%/C2W&E"PMG!678K?(K%21N\QB`3
MM4G!'3_8M95+WCR7^+F5K=_^!N81S*DJ25GS6VL[W'?\&I6X_LK_`!4D"DQ2
M^.I0C_PL19VYX_`C\Z_5.OG'_@ES^P;9?\$[OV3=#\`6]U!J6J>;)J6MZA&I
M5;V]E`WLH/.Q0J(N>2L:DX)Q7T=7/G&*AB,;4K4]F]#?+J$J.&A3GND%%%%>
M:=I^6/\`P=<?\F8_#G_LH%M_Z07M?ISX%_Y$G1_^O*'_`-%K7Y\_\'(_[.WC
MK]I?]EGP)HW@#PGKGB[5+#QK#?7%MIEL9I(8%L[M#(P'10SH,^K5^@_@F-H?
M!VE(Z/&\=I$C*PPRD(`01ZYKU\3*/]G4(WUO/_VT\S#Q?UVK*VEH_J:E%%%>
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M019(3#M\VQF3:V2CC[M>SEU2G4PM3`U)*+DU)-[771]DSR\92J1KPQ,(N2BF
MFEO9_P"1^FE%?G3X?_X+<?$+P'$NG?%+]DSX[Z/KL(VSGPWI8U>UD8=61LQC
M:?JWU-<]\4O^"B/[5/[:^C2^%/@%\`O&GPT&K+Y$_B_QQMTXZ:C<%XHF!PP'
M.X&0CLA.#6<<FQ*?OV2[N2MZ[FKS*CM&[?9)W_(_3>BN`_9@\$>-OAS\$-`T
M;XB>+8O''C&QME34M9BM%M4NY/9%P,`8&[`+8R0"<5W]>9./+)I.YW1;:3:L
M-FD\J(L>U?D;_P`',G[?5OH'ASP_^SUHFM6VE7WC-X;SQ7?L69--T[S,11/L
M!;$CJTC*!G9$."'K]4OBUXOF^'_PSUS6[?2=3UZYTJRDNH=-TZ(RW=^Z*2L,
M2CJ[$`#W-?FC_P`$??V`?&GQ._:)^)_[1'[1O@R6T\8>*]0>RTC0]>L@WV&W
M.TO((I`0%"^7#'W"QOZU[&3>QHREC:^JI[+K*73[M[GF9DZE11PU+1RW?9=?
MOVW.Z_92_P""O_[%_P"R5^SYX7^'GASXG0)I/AFQ2TC<Z-?*]PP&9)G_`'/+
MNY9B?5C7PW>_\%$_A'^R/_P65B^+?PB\6PZ[\+_BJOE>-K&&TGMUL)9I!YLV
MV1%!Q+LN`0#_`,M5XSS^XH_9K^'(''@'P5_X([;_`.(KQ3_@H1_P32\!?M;_
M`+)OBSP5IGA?PQH&NWML;C2-1M-+A@DM;V/YHCN10=I/R,.ZNU=6!S#!1KRY
MXRM4TE>2:UZ_#TW.;%83%NG&SC>%FK)WTZ;]=CZ5T75H-9TJTNK66.XM;J%9
MHIHVW)(C`%6![@@Y!JW7PU_P0B\4_%W1_P!E5?AS\9/!?BGPUKGP\<:?I=]J
MMLR1ZKI_/E!)#PQBP8^/X!'UYK[E%>'BZ'L*\J-[VZK9GKX>M[6FJEK7Z=A)
M/]6WTK\F?^"T/_*9#]C;_L*I_P"G"&OUEEXB;Z&ORN_X+>_!GXIZU^WU^SS\
M2O`'PQ\5_$;3OAVSWVH0Z/;%SN2ZCE$1<`A&8*<$BO2X><5C'S.UXRWTWBUU
M.+.(N6'=NCC_`.E(_5.BOSY'_!77X^`?\F1_&/\`\"!_\9KUO]BW]N_XG?M+
M?%FXT'QC^SK\0/A/ID%D]TNK:U-OMY9%*@0@>6OS$,2.?X37+5RO$4X.<K67
M]Z+_``3-Z>/HU)<L6[^C7YH^JZ**#TKSSL/'/VQOV%?AO^WC\-%\,?$?0(=7
MLX',MG<QL8;S3Y2,&2&5?F0D=1R#W!'%?#TG_!"OXQ?LI64DW[.7[4'C#PU:
MP,7MO#WB",W&GL>H#,A,>,\?\>Y->Z_\%)/B/^UI\$_'/ACQ3\$_#?AOQWX"
MTS+Z[X=48UF]."#AG.#&`05\KYPP&59<BO.(/^"[FO2:*+:?]E']H]?$ZX06
M2>'B]F9?0W!(.,]_*Z5]!@%CH45]7E&47JXMQ=O52V/'Q3PDJC=6+4EL[-7]
M&MSGOV`_^"JWQ=\/_MQK^S/^TMX=TFR\=7*,=)U_2P(X=1(C:10Z+\C+(BL5
MD3;\PVL@.2/TV08S]:_+[]C#]B/XR_M=?\%(K7]JKX\>'+;X=V_AZV%GX6\)
MB82WB*L<B1M,?X0OFR.<X9G;[JJ,']0@,5S9RJ*JQ]DDGRKFY?AYNMOP-\ME
M5<)>TO:^C>[72X4445Y!Z(4444`%%%%`!1110`4444`%%%%`!1110`4444`?
MD5_P=K_\D4^#?_8P7G_I.M?D1\,_]8GX5^N__!VO_P`D4^#?_8P7G_I.M?D1
M\,_];']!7Z[PO_R*J?K+\V?#YA_R,Y?+\CW_`.'_`-U/J*^@/A?UCKY_^'_W
M(_J*]_\`A?UCIXO8]S#_``GTG\)O]9'^%?4GP;^_%]*^6OA-Q(GX5]._##5K
M30M.-[>W-O:6=L@>6::58XXU]2QP`/K7PV;:Z'J4MK'0_%,9DD_&OG#XLZE#
MIBN\K[2[^6B`%GE<G"HJC+,Q/`5023P!7O\`J47B'XX7QA\&Z.]S8R9#:YJ"
MO;:8H_OQ9`DN?;RAL/\`SU%>F?!']CCP[\*]4AUO4))?$OBH*3_:=Y$H%J6Z
MK;1`;(%ZC(RY'#.U<.'Q,*$;SW[=?^`4TWHCYX_94_X)TW'CC6K/Q;\2]-:W
MTJ-Q-8^&YQ\]P0<K+>`'`7H1!G_KIW0?<MK:QV4"QQ($C4851T`]!3HXQ$@4
M9P/6G5P8G%5*\N:;VV78NG34-@HHHKG+"BBB@!KQ*YR1S0D*QDX&,TZBE9`%
M%%%,`HQS110!$;.,L25R3SU-2*H48'`%+12L@$90RD'D&DCA6$848S[TZBF%
M^@4444`,:!&?<1S]:>!@444`%1&SB+9V#-2T4K(!$C$8P!@"EZT44P&/;I(<
MD9/UHCMTB/`Z^]/HH87&O$LB;6&1Z4U+6.,\+C!SU-244N5`%!&X<T44P(S:
M1L02N2.A[TI@4QA,?*!C%/HI60$8M8PP.WD'(.3Q2O`DF=PSGJ*?10DEL`R.
MW2+.T8R,4_I110DEL'F!&1@U&;2,D';TQW]*DHI@`&****5EL`QK9&?<5&0<
MY]Z<B"-<`8%+119`%&***8$9M(R^XKDYSR:!:QA<;1@5)12:0/48MLBG@?J:
M?113L`4DB"1"IY!Z\TM%`$?V6/\`NY_&C[)'_<%244K(!L<*Q?=&*=113`*"
M-P(/0T44`1"SC`X!';@FE^QQD@[>G3FI**5D*RO<14"+@<`4M%%,84444`1M
M:QN22N<^_OFGJH1<#@"EHHL.X4444""F"!!+OQ\WKFGT4K`%%%%,`ILD2RKA
MAD4ZB@35]R,VD9&-O'IDT?94';]34E%*R&&,4444P$=!(I5AD&F+:HA!"X(]
MZDHH`*;)"LJX8<#WQ3J*35]P(X[2.%LJI!^IJ0#`HHI@!&X$'H:8;9&/*YI]
M%*R`C^RQ_P!T4J0)&<@8I]%%EN`4444P&R1+*,,,TW[)'G[N?J:DHH$U?<C%
MM&&#!>0<U)110,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#\BO
M^#M;_DBOP:_[&"\_])UK\B/AF/WD?X5^NW_!VP<?!3X-^O\`;]Z?_)=:\M_X
M)(?\$&K_`./_`('TOXA_%:ZO=!\*ZBBW.F:';?N[[5(3G;++)_RQB8=`H+L#
MG*\9_4,FS"AA,FA4K.RN_7=GQV*P\ZV9S5-7:M^1\N?#*)]2O;:TMHY+BZG.
M(H(D,DLA]%4`D_@*^RO@/^Q7\7?&D<,EC\//$,$,F")M3B738_KB<J^/HIK]
M8O@;^S!X#_9NTG[!X)\*:)X=MVCV2-:VX$T_3F20_.YXZL37?;!GH.*^<QG%
M,IW5&&GG_P``^CHX-Q7O'PW\'?\`@FUXY8POK_B/1?#D*X#PZ=`^H7!'M+((
MT1O^V<@S7T;X!_8R\%^![FWN[BWN_$NI6I#17FMS?:VB8=&CCXBC.>\:+7JZ
MH%/"J/I2U\[6Q]>K\3MZ:'7&'*,BA$/`Q@#``&,4^BBN0L****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`^'O^"LG[*%M^V5^T?^S'X0U&`7
M.A0>)[_5]7C(^62TMK5971O9V"(?^NE?;=C8Q:=;)#!&L,4:A$11A5`&``/I
M5/4/".G:IXDT_5Y[9)-2TN*6&UG/WH4EV>8!_O>6F?\`=K2'(KIK8F52E3I-
MZ0O^+;,:=",9RJ):O]-`HHHKF-@HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
$B@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>newgloriapicture.jpg
<TEXT>
begin 644 newgloriapicture.jpg
MB5!.1PT*&@H````-24A$4@```8(```!["`8```!Y$(?L`````7-21T(`KLX<
MZ0````1G04U!``"QCPO\804````)<$A9<P``%Q$``!<1`<HF\S\``%SL241!
M5'A>[5T'6!77UO7][[WT_E)--:;'F)@>4XRF]V@T3:.Q-Q"Q`@)7!`2[J*C8
M4!&0#M)[+P(J8"\H8L&.)9K$E/WO-?<>/`QS+R!H,)GU?>M#9\[,G7OA[G7V
M/GOOTTJ'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ
M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=%P*C$ZLNMZ0?.*!26E'7W!+
M._R!>TK5MQ[I1P9XI!VR\4P_,A+$O]W3#PUT33WTW>3TPQ].SCCZDB&]^B%#
M^N$;3+?1H4.'#AU7`EPSC]\_.>/XQ]-S3CC,SCL1X)5WO&A^P8F#2XI._.*W
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MAXBRF#D'?Z.<`[\P?Z:<_3]3-C-KGXHXQL28W(._4'[5+T:18-'(9V.?PTP[
M0A3''D+8SE_)KZ3Z3[_2DS^M+#EQA#V+_?/SC^Z=G7WT\*R<(Z?FY)\XS8*P
M:U[!J=7>A:?ZSLFL:F,@^C_3H^K0H4.'CDZ&]/_,6WO2:7;.X84SLT\^;#I\
M49B25?V.5T&UGT_1J6J$=])XUI^Q_SQE5IZCS+UG*;WB+*6IF+[W7`TS,&[?
M.44<<@[^2CF'C5X##/ZJC6=H<6'U0>_\8YDS<X\MFIIY=(Q[^K'N+LG'7[-+
M/O+8F)C#=_?TVW%3)]\]U_0(IG\',PWIZ?\QK"F^SBOKX!T+"DX_Y;/^7,>Y
M><>?,01ONLKTR#ITZ-#QS\:\HA-?+"P]LWMN_O&(:8E5UYL.-PK6<3NNGIIS
MZL=Y:T^O#=AZGI(.L@!4_DII>WZB5&;R[C,FXM\_48H@GP,Q!H*0P4*1N>\7
MRF#QP)K`RK*?:'[AB>VS<X_[>F8>ZV](/_S<L&!]85B'#ATZF@63D_<_-K_P
M3$3@/J(YA=7S38<;A1<&^?S7,_OXX+D%I[>%EA,E5?Y)R>5G*&G7:4K8>8&)
MN\[48A+&F)C*@J!X!@?^H/@#1,O65?\QMZ`Z=WKN23N/C.H.F-F;7DZ'#ATZ
M=#07IF0<';VD].Q/:XX1S<P^XFDZW"BX91SIX95?O3%D%\_>]YRGA!VG*'[[
M*8K==I)YBN+XWX(X'H_S"HWB`+%(V7V6$EF(5F__G;P+JK=.SSEAF)1Z_&G3
M2^C0H4.'CN;&I/C=C\_*.YD6PS/OM!/L">0>G6$ZU6`8$BO;3<\\&K=R\V\4
MN_LWBF/#'[.UFJ*WGJS%&!#G3#0*Q$E*8%%(W/43Q>XE6K+N-,W*J8[WR#SZ
M!=8I3"^A0X<.'3HN!3S2#_^XH/C,J2SV`O)/$7EE'UUF.M5@N*4>MI^37_US
M9/F?%+VEFM9L/D&1FXR,XG\;6:UP#<Y+A%C$;3]-T15$"PNK:6KVB0"WE&,O
MFVZM0X<.'3HN%3#3GIYU8D'@3J*U+`)%9U@$<H\DF4XW"';AY8]Y9!S+\-_Z
M)T5M.4V19<<IO)2)GX(;CU-$#4\H5`2"&;/E!*W9=9Z6EIRCJ1G'(U`];+JU
M#ATZ=.BXE#!$[FT]*^]D%D)!Q4=_IW6GB;P+3^P8%%Q^LVE(O7",V?OU].RC
MU:';?J.(TF,45G*40DN.U6(8B',L#C(C610@'(';_F0!.%;BDG+D(]-M=>C0
MH4/'I88AKKS]W,+3NU..$*T[>I[651,M+3W]\[C8RF=,0^J%4]R^2=Z%9RAT
M(W/]$0JNQ:,4LJ$V0P59&!31V/8KS<PZ>GY2\B$G9!B9;MLT&.C_K...W60;
M77FO7<+A1^P3#CP!&I*//#8^^<`#=LG[__=AW(ZK3:-UZ-"AXY\)]Z3][RPH
M^JDZ_3!1T9'S5,3>0%0ET<3$ROZF(1:!<))C[+Z`)27G*7C#,5I=?)@"BYC\
M<W7QD1H&K:O+$!8)>`.K-O].'FF'"^TB=EUT&,@FHNHAN]C]GSK'[[.?E+A_
MI4?2OJRI:57;9Z15'?'*J#HW)[OJ=^^<0S0_]S!YYU3].2_G\*_>>8>KY^4=
MWNN5=ZQH=N[QL%EYQSQFY)W\WB/C^#.&3:07D>G0H>/OC\G)^S]=6'SFU_2#
M1+D'?J8\9BI[!5/2#P69AEC$()_BZYQC]R<L*SVO&'__PD.TBHF?,@.*P,,*
M%9%@!K%0!)>>I/F%/Y%SPD&O%WR*&^4%]`^JO&U,U($O)L3N\YZ8N+_$(WG_
M+PO6GJ:59;]0X*9?*'CC3Q12=II"RTZRV)R@\#*Q%E%-49M.4M264Q2][0S%
M[#A'<>6_4ES%GQ3+`AA>3N2[_B0M+#R^9V[!B=73<ZO[N696MS&]K`X=.G3\
M?>"1LO^SA>O/_)ZR[W?*V/N3TLXAX^`?Y+WVQ"';A,K;3,/,HM?*DNL=8RLR
MEY;\0JO65M'*@KKTX^-&'E*X"F1A""RJHH#2,S0E]<C/XR-W]S;=LEY\Z!5W
M]<C0\L_&K:D(<(FK.#HGMYJ-]EGR6U?-]SVL/(="28`@.L(C$2$JXUJ%<6T"
M"]98J$96DY*MA+35G6<H:<^OE+2?:$T%T=+BZE^\"T^E3,\[/<`^[N`=IL>Y
M4H`^2:^J>#M3!@KQ.C+%^>>8EO`OYBM,,?XM9KU_,W]CW,D4G\5KS'N9EH!P
M)++@Q#7MF9<#CS'%:X(W,=6XCXGW(,;<Q=3Q=X1GRH'W?-:?^0W%7<F[4,U[
M6FG=L'KGG^266M7#-,PLK+UV7&T?59&^>/TY6IE_@'QSF7D':'D-#RI<D2^S
MBE:P./A#-$K.TJ3$@_ML@[8W*"6TI]^6>VQ"R^T=(O;LG)%YC)84GB+?_,/&
MU\W=3\N4G\;7QNL81<@H.@&*\%P(3REB4'+4M&AMS&(28H"45J2OHK8!=0PH
M;DO<>8I2=I^CU`,L"NPQ+%I_YMCLM:?F3<HXWN#UD[\8,-HA3)(8QY0!L4AF
MRF,LO;_OF?+84\R[F4V!+7,)<S$3Z<I]F0*3F.)<??1E?L.\G!C,E#\/%Z8E
M/,B4QV]G7@[$,.77[<)48S)3'F/%U/%W@UO2WA>]UYT^&X-PR+9JI8`K?CL;
MOKU$4S.J$DS#+&)L1'GDPJ)SM)R-\-*<VEP&*L;Y@H$6A&@LXQF\8_R^S<-6
M;<:7P2)Z+BRZ9UC0SBGV$;M.S,D]28MRC]#BS$J%B_`S:S\MR3:]KNDUU&)0
MXQF8UBJP>&WT"M1B<*'&8<T64Z&;4MAFK'9.W'F:4LK/*'V1DJL0/CKUAU?^
M*?])J8>?-3UN2T9;YGFF_`57S_JQ/B.?7\HTAS*F/'8$LREXDBG?#WR;"=@P
MU>?J8WT>37/C.Z;\^F.8EG`C4_Y]E#`O!R*8\G.*SUB&*U,>,XRIX^\$U\S]
M]WL7GJR*W'F>HI##;S)\,=M.TZ)UIW[SS#B&+Z1%V(;LF#.GX"=:FKV/#;',
M_36&6>92DZ&&:"PI/D,.T97K^RY=;S&\@JRA@:NVC1L;6GYT5G8U+<@X0`O2
M*FA^VEY:D+Z7%C)],LR(@<DCJ1&#FC`1%K"%5]!X,4#["]$+*77W&4JO_)E2
M#A$M+3G]^\S<4_,=PBKN,3U^2X474_Z"^S/5"&.*\V>96N_I,Z9\GUW,IF9Y
M80(BWW,.$_B0^0=3/H?G$H0G\C-3/N_,%'B*"<_B1POLRC0'A'!@Y+6N$^S#
MA`<C/T,X$\?-C1_-_(TIQN]C:HV5B??Q"+,IP'/)SZDE!/"^Y#%#F3K^+O"*
MVW'UG(+CQ6$[_J"P#4<4(RA2-[%`RM[``M-0LQCNOVG0E,QJQ?CZ9+!!9L(@
MU]`T4S=RGY$L$A"-186GR3YJ;\D/<]?^SW0[3?1>LJ&S5>".#1ZIQVA>V@'R
M3MY-<Y/WT+R4/>2=*HE!S>L91:B.&.0?9`_D0HA(B$'=]0*(@7&]H+88&$-$
MLA"@_Y$0`S3!0\?4C'V_*)OF+%KWT^$IF<<'F-Y&2P3BV*>9X@N.&:EZ$1SA
M(-D(3&6JD<>4QWS+;`K4896-3.`#YCFF.'Z0B;6(UDS$X/$3SU_)%&/@J<BB
M9,\4Y\SQ$-,<\+>J=<U?Q4',ID`7@G\ZIF56K0C:0;1:"9,8#6(P&T1DU<PK
MJ#X[)><HOEAF,21@<P>'-16_+<PZ6#,[%X1AEHD9.T0"7)S)8I%_@NPC=Y</
M\]UD/H[<H\>_^RW?-&5L6#G-2JNB.8GEY)6PF[P2=].<I#V6Q0`>B<G[6):C
M'2*ZL%Y@9O&8A0",8#%0KQ=8$@.TR,ZH^(DR#_Y!X15$L_).1HZ-W&KQL_P+
M,8$I?\G%S%N&-[."N8>YEBFGT<)PR-<7,)N"-YARB.0X$R%#".J?IF,@Q$=K
M[PLWIAB#^ZC#=`Y,<=X<CS#-`8OJ6M?\581H-@6Z$/R3X9YZ8*#OIM_)CXWB
MA6P>&,8J6KWM#YJ6>43+(-2@CV_Z-2.#MF^=FW64YJ?P#)T-,HRRD16*<98Y
M7Q&*"EH(YAPA^S5[JP?YECUANET=?#8MLTW_E9NS)R4>H5EL_&?%[Z29\;OX
MW^4TNP%B8`P1[;O@%6B(`3*6X!4$LA!"!%##@((V5#^'EQY5/".(@+)P7"M$
MI"4&Z(IZH4TV]DU(8S'(JCRGA(N\BT[O=TDY\)[I[5U.8&'X&@M$2.X`4WS)
MSS`QJY;'P/`C`^A6)KP([.F`X]B)#NU&Q+4(V2!,A/'R]8(8;ZDM.#)3JIGB
M?O!6$-N7Q>H$$[-Z+71GBG'@#TPU\!H3ZZ$UTQSP'NR86M?)7,.4GR6-J35.
M<!;S=Z88#Z]$:YR:35W[T(7@GPJ>Z3\^.^_$S\O7'C4NY)K")S"2*PN/T)R<
M8[]ZI%<_9!JNB2&KRF9/RZRF>4DFHZP8Y@N<:S+2,KW98"](WT].L94T<$79
MNZ9;U<%7<PK>'+1B\R&/Q"J:$;N#IL7LI.FQ.VE&G"4Q,`D!4VN]`.]1>7_Y
M!Y1T4O^BHQ2P_@0%EIZFU65G:?6FGVGUYE^9YREHRV\4LNTW"MO^&T4P(W><
MIS7;?Z;H[3^Q\3]%L5NK60`@`H+2>@'23"$$)L\`F5=9E6<ILXIH6>DY\L@\
M/-ST-B\78.B1@8*8LQ9W,V'\Y2\Z9N$(KX@Q\`;*F1@+BG/[F?)U$`*<%]=I
M\6NF%CYA(L8O[H7[B&)"B$T5$\:R'0XP(#;8"$FP&U-X$O`<T!X=F4_7,<68
MRUDQKLZB&L>T!(BK/'XSLZF`,&+1'L0ZA!::2PBP=B1>"XOY5T+"Q#\81/_R
M2#E0L&S=&26F?R&FOH^6,E>4_DR3TPY8+!X;X%OZJEW47O)*JE",LN!LDX$6
MA*$6A%!XL\'V2#M.@_Q*QYIN50==O0JZ#_3;_(M'W%Z:MF8[35FS@Z9&RV*P
MJY88***C"$%=KP"91%B+\,T]2,O7'J-EQ:?)I_`,S6(OQC6VXOS$V-W[G6)V
MKYL0LRMA0M1N?\?H/0LGK"F?Y11=,=,I9L]LE_B]2]P2]@=/3MJ?-C5Y_Z99
MF8>.>N<>H54L&)&[B>+V_$$)Y><H`=X`PD.J$)&RFYII!S5LLYEU\#<*VD4T
M)>,(TO$N%Q"2DK_$?S6',+4PERG&K&;*R0/P0H">3`@2U@8@#(<ERJ\!0KPP
MJP8Q'D2ZZ>4"^F+A62&6\+A&,BT!@H5,(8P'4YA-A0]3_DRT]NIH+B%P9,IC
MM.ZCHZ5@8D+EZ(7%ORBS<SEL`^.)6?3<@E/DGG:DDVEX7;"0#/4K6S\]I8IF
M\0P=LW0C=]$,-M`PTD:6*Q0B,8<Y(^,X#?7?%&VZ4QUTG9G3<[#?5IH<LYL\
MH[:11^0V_KE#6PQ,0H`U`UD,\%X@<,KB==YQ0H&92VP%.827[QP=MFNU3>C.
M45:AY>\."*IHTSVH<9OL#TH^<?.X^*JG#?$'N[FG'9XT->MHPMS<(T?\V)N(
MJ2!*JCA?L\.:EAAD[#U'V0=^I3`>.S7S\&S3;2\U8%!+F3O,<"L31E7^$F-F
M+\YO8F+!51#>!8[C)SP'^3HLY&)A5URKYD[F5TPM3&>N9R*T)("BJH^9,"KO
M,^4,IHMA,!.+RK@G#+46<0X+T!<#%-2)>R/SZ"4F_L9@Y+7VRX"'@@5P7`./
M"#\Q%M<@E-94X'W([W\\4XWF$@*L#8GS$&%]?Y"6"D/R@0<\4JK.SDW=ST:T
MW#A;5T(Y;$39D"[,.4IN"95;8.Q-E]1!/]_2'PWQAV@&&^5I,3#.@D8C+5.(
MQ$SFK.1]-")X^]%>\TO$[*X6/IN5W:W_BBWD&K6+W".VDAMS,@N!!PN")PO!
M%`@!4]Q7'2+"\R^`J&4=HIE9)VA\V*[?;$)V9@P/VCYF2,".#IT,=$G^,&TB
MJF]Q33_VKF?&T9ES\X]O]=OX,R7L(TJM^$5)*15[+1O%`/LJ8V/]7RB4Q<`S
MXY!6!LZE`$(DY@AD,N4O.O+&Q7EX%'#[05%1*L[!_9=3.1%B>I0)B#%JFOO;
M4J</(Y1SE"D_5X;T[V(FPD0@C*F<>HFPC#BWTG0,Q):J`Z7_FR-FY(T%ZC+4
M::TO,BT!SR>/AU@V)R`J6/@6]\<ZA1K-(02H//Z5*<ZO8.IHJ7".WAWJE7N*
MIL=L-QE4GEF;0BVSF=X%/]'$N$J#:7@=H'IX\(K2"L_X2IZE;V<#;0S=R,3,
M71"&&R(Q,W87.<<=I+Y+UR/_N@X^FIKU>J\E9>==(G>16]@6FA2VE5Q9""`(
M1C'0"A$9Q<`H`A7DE7Z87.(/THC5V[<.6K75L9_?UL=-M[]\Z!'\;Y>,HYUG
MY)Q8NF#MR>KH2J*T?;\IB\;"*TBM.$N9E><HB\5@]2ZBR6D'1YFN_JN`7'3Y
M2XZ9/@RV`#R7DTPLXL(#P"Q7!L1,OMZLQ]=(J(W/%*9<2);.%("(R)E&<@4T
MU@K$<60_(30E_F^."#4U%GC?\CWP_/7A"Z9\#3R6YH:\:(W%=W7;C^80`JS[
MR.<;W")&QV6&4U3%Z^YIQ\@C>I=QEBT;5R9$P2UAWY_VT968I6BB[]*R08ZQ
M!\F3C;-[I-%("R*,`X,-XMZ"4R$8254T<'F)YF8V76:DW-MC7M%AQXARFA2Z
MF28R)[$8N(8;O0+W"./]:STOBP&\#"^$FU*K4(M`@_VV9O3QW?A5JQ:R9>78
MR+VMIV0=<YA?<+(2;2C2]_]&Z2P($`-LM@\QR-A_GI9N_)4FIQY$2."O`&+&
M\@(M9M6(PV/FCQ`*J/Z2P["(<R!ZU2`4((]!:XBF`'^#\@P3,7:$2N0:`'EV
MB]Q^>;P<"_=@BN,H\D)ZJI^)\!:P@"W.@VBY`-%I#%`W(=\#(2[Y[Q`M&?"Y
M@1",14P`;2?DZ[".@'!1?<1GT="_<_PNY-=0)VDTAQ#,8XISR'P27J&.E@;[
MR!W9GADG3$9V"[E)AA9&?%K2?G*,VBT*=^J@1S#]N[_OAAVNT15\K=%0*\;:
M=!]!S.(5FH3",WHG9NF_]5RZ'A6=*M"_/IN9FSTV;`^YA&PB`W-BR&9R48N!
M26B$&,R,W4'3$RO)8<T^&KAR<\X/B\O^*D-:+[")S]2LX^,6%IX\G'"`*'/?
MSXH@0`RR]YVCE/U_DM?:$R<\TX_!O;Z<0*@'BYGR%QRA#<SZ$>L7Q"Q2SM\'
MU>?Q4SX/?LF\&"![!ADSXCZ_,(5QDEL=X#EC380HR&&97*8XA^PC<3R4J89Z
MW:&Q764?8"*E55R/ST*NQE>'?T!A2'.8\G$L:.]M`)&UA<79A@"]N^374%_7
M'$)0R!3GU!ZECI8"N_`=[T]*/4:&-;O).6ACC<'%[-MH=#?3%/86[*-WF]V,
MOJ?/NL_'A%60*QMH7%-#)90C41$)HQ&?S$8<X9H^2XH7FFY3"^]-R9PX-'`W
M30S>1$Y!F\B9?QKP7&;$8,J:;30]9A=-C#M(`U9LJOQVX7IS*7$M#O91Y7=-
MSSTU=WGI6<HXQ(*P]RR+P3G*83&(VT\T+?.P5OSV4@$%6K*QO12$=V%N8=@<
M,-M5-[I#F$94!JL-4F.)1GMJJ$,ZC<G+QZQ<7B0%Y>9VJ)E8QY3/PRL`[F?*
M7DQCB?8@#0'66N1U`O'Z`DT5`GAC<G4Z/"T=+1&C@K9FN:>?(*?P[63O7TH3
M`LO(<?5&<F11<((PL`%V2:BBL1&[S,ZL>_L4QSJMV<M&FHVU8K`%C89;"(L0
M%]`U8@<-6;'I7,]%!75FNYW<TI_[:G[1'Q."-O.S&)_'DA@@'#4Y9@]9!^VB
M;Q9L6/S.Y&2+;2E:*ESB#[SI771J`UI08-$8B\?P$E:7*WL^F$NM;$Z@M;0<
M#L%L'XNHB/4WE=.8\@P<;&B8"#/K;*9\+8@%8[$UJFR0T,\((1<0ZUIR,18R
MD,0Y"*PXWMQ"("]$PZBKJWRQOB+?&S-^L2CNQ)3/'6/BO6H1AAP]E.3Q>(\-
MA2RN\`+EL%)3A0!_3_(Y?.8Z6AI&AVQ_94(,BKCVTLA5I31N58G"\2P(=DS[
M`#;"P5MI3/"VLZ/#=FEF]/1<5'K?@"7K?W4.V4I.BL$6-,WD309<)D(]3M'[
MZ0>?(N0RU\&[4])S1Z[>28XL2O9,(4ZUQ,`D!/`LG*,KJ??2LJ.?>Q6A2.:*
M1B>#[S73LZN]PLK_I-Q#?R@AHN3*WVAV7O7)V?F'+F6O=S0VDQ=5$=M'VV$4
M#R+KI3GX/!,A&=DXH"Z@OI;4B,O+UPC"$&H)02H.F(`>^O+L6DX4<&>*X\TE
M!)CI0_CDZY"&BQ@_ZB'P.NJP#X0*ZQ,`PE]RRFXD\Q8FWJ<Y8@%6OE]CA$!N
M(XW?O]SEMZE"H,["0N6VCI8&:_^-_I,SJVG`RC+ZSBN'QOF5T*@5ZVGTR@TT
MQL_(">'E-"IX&UQ837RWH'C8J-`*9>;NP`9;$,9;(;P+B1`+0\@6&K2R[(]N
M/L5UVDB\[I[Z=:]EF\F!10B"!#$2]W-<;1(74_@*ZQ'C(BJIQ_SU!9U=4V%H
M_C9P33[4<T793^?RCQ+E[#M+D94H-JO"[+PY@71-&"!UBN@JIMB,1EU9W!2*
M7'54TLH+T9@-8\9LKG8#X4.,P\1!7KMHB4*`CI_R-0UA+Z8`FCF*XYCM:W5T
M50-K+O+]&B,$J+J6KY47C)LJ!&A%(XXCNPQM2'2T)(P(*+O+)G#K6=>D@_26
M(9Z^G9E)MBP"(Y:M(QO?=31R^3JRY9_V495D$[(-&16:^&Y^8>*XT'(VV*4U
MGH0=_QO$,2.-,WL8=$4PPO?0]PO7ULD4PG[&[TQ.WS8R8*MRGW'LI2B>2<VU
M1J\`X2=X`R-"]M#G7FN#'^SCVQP%-BT.=FO*7_+=<'I?834I^QK,R3]Q?EIF
M57-N@XE0!!9<Q9<5"0%(6Q1`7!Z3`%'1VE3*H0$LFJH78Y&5I(7WF"C(`K8P
MQ7AS0H#0$-))063?R*&AF4QQ#FFFXGAS"8'67@D@JICQO.KC<EL1.7T5[;)?
M9S8$ZCY*C1$""*.\F"X_3U.%()$ICF/16$=+P^"5959.2<=XMK^5VO3UI3YS
M<LAJ:3$-6UQ$PY<4D173FCDN<A^-"-JF&<O]9'[VK;T6%)X:%[B)QJXJJ:$Q
MQ&0TY"`$0A`S_1%!Y=3=N[#.KE"ON:3V^';Q)AK/UX]9M8'OQ==`#"`F)C&`
M1S&1/8JA@>7TT<P<S87FOQ.L@BK:+%U_9ONZ4T2LR>P5'$)XH;F`]1E\26$X
ML:&(U@;\6(S%\>:@5L$89J"B.5U#-JQ!894P+K(08`U"'+\8JG=A`R[6(T"5
M=103=0I(6D!V$-XG.K3*]T/H1(98L\`BN);1-8>F"`'$'B(MKI4;2C9%")`=
MA"PA<1P[P>EH:1BTO"37-?4H?<6>P-W?+E"$8+#/6AJT<*WR<PASZ*)"L@W9
M358!6U#B7@==Y^:_-W#%%AKK5Z*$DV2*T)*1+!`@&_CQJ[>P-U!T[/,I.=AU
MJ1;><$W)&^YGO!^N,XJ*R=-@,8`08(U@L/\N>G]:%O*3_Q'HO7S#O2O*SFS+
M9<]@=O:1DS/RZM\CNH'`HCKRW%%E*@,+AO%,&#3DO<,K:`ZB7P[NJ=7Y$VTB
MZJNVA9"8$P)X$S#<(B<?A#&&R,@S7H3!<%P>!VJU6+@8(=!*CT0[!X2_Q'VP
MN"M[7@*806/3'1&GA^%%;R]1VV"N*6%3A`"0/2.LX0@T10@06I0SAO[JXD@=
M:@Q<OK'ML)6;?G>.W4LOV(;2O3T7T?>SLJC?_'SJZYVO_.S/'+BPD(;YL>%=
MN5&S6V#7.?E.PP-W*>L*MLN9^&DBCLF$.(QEXSXJN)R^FE>`!<):>,XQX=E/
M9N;1:-4ZA2P&\`:&!.RB=SPRD9'QCT*_59L?]-]T:G_4(:*I64?4,\GF!F;O
MZIV\FI/RKF"-@24A,`<4MLFU#EBP;B@N1@C40#MH^1X(D9A;SU)O#M^:*;?'
M`+7V66BJ$*"J6EP+H19HBA#`9LC'L7N<CI:$'Y>L'S8NIHI&!&RFA_KZT@.]
ME])7T]*I][P\^F%.+O6>:V2_A44TP+?D[$"_+9H+5EV]\B*L`[;32%_CNH),
MK#$8N;Z&HU=LH"'^.^BSV?GRXIB"%YT2/7LOVT)C6`",0G+!LX`8.+!'8!6X
MD]Z9FLGNL^$?693B%E_Q_-)-/_TV(_MP4S=X:0@0DT?64'/S'>;%>C3FA`#'
M\3>!GVI^SI0-$F;56N/$]3*:(@2(O<OIJ<C(P5H;A`F>&)KFH8$C%GJQL0XJ
MH[5"8W+K##"0J493A0"S=7$MO"<A2$T1`C36DX]?_K8N.BRCSZ+BJ`GQA^A;
M-OKW]5I,#_VXC#YQ2Z;OO7+HVUG9]-UL(_LL**;^2S94]5I9@L(3-?[UI5?>
M)NN5F\AZ:1&S^`*7&3E"(L3!=D4)?3.OX/RGLXN1%RZ!_O6:2^+FH<O+%,\"
MHB&+P7C_$K(-V$;O3LVI?,GNRJP1:"YX)!_L[5U\CF9GGU!]ALT&?(&Q7H#F
M;`@;70KV8\(@@XT1!1AJM1#`@..9T;T4YV0B1HTQLD%"]@J.J\?B>NQ@)N-B
MA0`BJL[M1^82%N.1&BHOT,O$HK9ZDH,8OKI-ASJ$UE0A@)&&EP9BES81MFVJ
M1R#NB2RQOV5"QQ4+&/4??`H/.T17TCO.<?10GZ74YD=?ZNP42U^S"'PU/9.Z
MSS"RY_QBZK>X>(>!J,X,_!./[%N[>>56#U^V@88O+C(N,IL6F@6QX*Q0$8HB
M&N&WB;K-R:O3JN*Q46N>Z#PY[4\;%@`;7Z-H"#&`AS#6OXP^\UI++TR($[G6
M_VC,R#P4/#WKT*6*N:(MM?S%OM24F\#5!RTA`"`H\CTOEC!\,BY6"+`&(E]G
MB1`,I,2B8`Z;ZZB]$@`>M'Q-$5,N_&JJ$)A#4X1`1TO&M_/R7^FW?!.-"=E!
M+XX,H<<&K*!'^B^G5\9&4%<6@<^GIM,7)GX[?QWU7E2,!;XZ>&=ZUF/=9N7\
M.71QL;*PK'!1H;+`+'/88M`H"$/]MM%GLW/JM*%]W"ZV[Q?>&Y1T5<634,)+
M+`0L!N/\-M`/OEOI%4/<Y=RPI45C6F[5G=,RJL8;#'4%NAF0Q92_V)>:&GVF
MS$)+"#!C[L#$;![]A@2QA:6Y]P*QP\Q7'H_KU3V0FD,(T)D5'@@6J;'@B]?"
M&@_:8R.;""F\]36)P_M&]U$(`(COI-SI51<"'8U#USFYPX:%[*6A*TNIW5!_
M>GK(*GIBD!\]:[V:/O9(5?B)B=WG%E&OA<4;3)?60F?/S(X]O(MHL$\A#5Q8
M0(-J>"'S2!`B,8Q%H?_RK?3AM)PZJ:A/V<<M^&[11AK)(H`45A%*&LT>P?"5
MF^E-U^1MK0;YB)XR.AC3TP_<;DB_)/LHR,83\6*X]B*,TQS$WY-L.)HJ!*BZ
MU0(6O.6Q,A&>:4B(\6*%`&$[&'J\-V3/:,WRFPIY?V=="'0T#E_.SEUL$U%)
M/\POH*<'KZ+VPP/IF:$!+`C^]+8AGMYW3V$FT_MNR?3E[+7TG7>AID?0:7+Z
MAU\O6$\#%Q10?[X7.$"0CX$X)SB$!>/[1:7(^*F3BOK,A)B,'Q>7T@@6`:5^
MP20&6"/X;$XQM;>+T3,.+A]D(4#&2G,#^>2RX6BJ$&AE#6'=`>FJ8MQ/3%30
MRAOQ8Y:.K!Q+:,IB<7U`S!QM6Q"?1T\>>",PHHUMQ@=<*B'`PK1\7ZWWC[1;
M>4R=1!`=+1!?S,K)L0FKH&[3,U@`_*D#>P+/64$,_.GEL1'4Q369NDQ*I,XN
MB?3)S'SZQKO0C$>0T:W'@@W4SSN??IR71WV]!?.58S)%*FI7KSQZRR.C=DRX
M1_"_VT^(+Q^P>(,B`F)M`6&B_KZ;J,.$.,V]"G1<,J@]`K2U0%BNN;B-*1N.
MYA8"M%:6NZ<B6T=,/EYE(E0CSB$V;W[KU5:M(IAB+(@05'V`EX;T4#P'7A<+
MX\@(0I,Y&%;L-XS)%=I%RWGV@E@K:"P^9<KW0/6T.<`CU_J]:%']N_)GJL>H
M^R:A#D(]QARQ;:>.RXT>P9NN^F1F3N6(D%WTL5L2=6`!>-$FF%X8$:0(0@?K
M(.KH'$]O&!+H#?[Y_I0<^FIN_E;2V)[R#?>4[E]YKZ<^+`(BW;3WO%SE_X(0
M"(4L$/T6%-''TS/.ONF662L5]2;;A-N><XRO'K1X7:WU!*P1O#<]C]J.6:,W
MJKJ\N-+6"$2J(^H#T(M(KAF`(5,G&&!C&KE'/HBZ%+1SP)H+6D"CXAK-]M1M
MI!ORK-AX19W[WQ!BT1CO39VY)"">2XOJ#6;00\D<M#;S_ZN(ODHZ+C<^F9%W
M[R<SLG\>'KB-WG..HY=8!%ZQ#:&71H88!8'%X'GV"EYT3J"7'./H3?<,8@]B
M7Q_?]#JI7V^YIW;[<NXZI>Z@YYP<ZJ4P5R&._<#"(`B1^)&%X,.I&8<Z&=+1
M7;$&-]L$/M3!,>'7P8N*:>@B8S4S0D1]EVZD]HYQ6&#3<7F!2F*M+^VE8F.S
MAN3P#HK>D-J,6;A<`(<-6K#)2JV_-0F(KULSU3->W`LS5?F8(-IP-"0%$F*A
M=3W21]'*`8N]Z+&$_3VP9@*O`34%6#2VM/@O-\BKC^J=QF3([23^:OYCN@.T
M*+SOD?KL)[/S:>BJ3?3NA&AZ?708=62^.BI4$827(0@C@ZF]730]XQ!++TY,
MID]G9)_\SJ=8=**LP6LN21]\YE6HU!Z(N@-!'!/LR81(_#"_F-[US-CS5(]@
M+.+5X'\V08\_Q\(S>%%13>81A.!#KV)J,S:JAVF8CLN'-YF(5U\NUFDU8@$0
M`H1K1,L*=!F%<48B`8ZC#Q,*R+3J7K2`Z]#0#FVCT=X!"\^(V\-C0&817@/_
M#F`V5+#0%!#W6LRT8Z)N`EXMVD:8ZZ[:$."Y\IFH_%43X5L\*\).@YB6@((^
MK=_#7T%YVU`=EPN=/5*[?#JWF`:O**/W'**I$\_^WQH706^.#:?7QX31:Z-#
MZ546A!=&A=&C+`9/38BC]Z=E_M%]5DZ=JL#7#`D=/YR>2]_.RJ&O9V8I_`:<
M!68KA6F"BCAX%]$[D],P`ZN%&ZS\GWC&*8X&^132X(7P"-;2H"7KZ5G'^*I6
MW8.:\L71\<]!G=#E1:*Y[J-#1\O%6VXI73_QWD"#?$OH`_8(WK6+HG>8G<='
M4J<:06"R(+0?'4[WCUM#[\S(IZXS<]$:H!9>=(Q_O(M;RI\]9N;4*D+K/B.+
M>@C*`C&WD#I/3L$&';5PM75X6Q:<WP<L+%323H<O+J0>"TNIS?@HL8FW#ATZ
M=.AH+G2<F-SSX_DE-&#9>OK0,481@_?9,WC/G@V^21#>9D%X"YX">PB/LV?P
MVO1"^G1F#GJAU,(S=C&WOC$IL;H;"T'7:1D*D8ET@9F*0"@BP>SAM9;>=DO9
M_8*Z'F!$U%UMQ\><Z;N@2*E#&+:HB#I-SZ?;1T9J=CS5H4.'#AU-P*O."48A
M6+J>/G:.I8^<8NA#4!($>`E=6!`Z0Q!8#-Z>G$/O>&8B]:T.7IV8M.GS6?E*
M%;)<D?S%M'3ZDH5!$"+QU:P\ZC0IY6#[T8FUX[=]?*^Y?VSD_N^]C:&A`3Y%
MU,XAYDRKX2O^T3V%=.C0H>.2X"7GN)X?S-M`_9>LI\]<$NC3B?'TB2'N@BC4
M>`DL"/8(&T72>TY)]*9]%/J5U\$+AJ3PCV<5TF=3TNA3SS3EIY'I"C\'32+Q
MY8QL>MTE^:=V]BEU]MV]8U1X4=>YA31L82%]OW`]W3\N.L]T2H<.'3IT-">>
MG1#7\]TY1B'XPC61/I_$9$'XS((@?.`83UW&1AQY3SV39[1WC'=Z=V:1THY"
MM*>06U1\PN(`@0`_GYI);TQ*_O,I^[@ZN=@WC`@+Z#)K+5DM*J3/YZVG.T=%
MHC^Z#ATZ=.AH;K0;']VUTZQUBA!TFYQ"7[HET1>@(@HL""[Q["6P(+`H?,2B
M`$'XT)'%P9!([SI$H2JS%IZ>$/=^1X]L^FAR*GW@GD(?"O*]01P7A!AT\LRA
M=DX)2->KA6NL0\8\YY%'PWW64N>9A733B%!Y;UL=.G3HT-%<>&Q\5)=7I^13
MWR4;Z.NI:?251PH+0C)U=4\VBH+)2U"'C;[PR*$/G&+14[P6[K--N(V]@M/O
M>:33>V[)"M&CR-BOR$@(!/@1"T/GZ6OIJ0GQ***IA6NL5K]^GT,B]9M?0*^P
ML%PU/`0E\U<</IV=_4#7V;ER5\B_&Y"SCY8.J.:]%`WOF@IXK:@%0&W"I>C,
MJD/'E8\'QP0_]]RD-.K-0O#=C$SJ,26->GBFLB"D*AZ".4'XTB.+/G:*0_%.
M';1WB$YZ>THNO>.:1%V8^`F^*R@$@N_=97H!/3TA'FT`:F.0SW4W6H4<^L*K
M@#I,2J56`P.PL<<5AT^G9R_Z=&:NUGZ\5R*0W=69:6!&,D5_G",FHD]/!A-M
M`E#$A-^9N4UF4*2&_C>HI@7Q[R>8306*M["#%RIUL<\%]@4^QCS$1+L&]*E"
MV^>&_CW=S13/:(YHZ.;$_)&)?D+U51MC@Q_YO:-X[59F0X&]C>7K!<UM=ZE#
MAV7<9QMT[^/V<3]_M[B$>GGET+?3,NB;:>F*=P!1Z*Z(@M%+^-+=&#;ZG$7A
M"[<4%H2$<Q\;8O!%J87W[:.L/W+/IB[.<?3VQ$1Z>U*2PLYH7,?LPO\&W\%/
MSVP4J:'$O@ZNL@H)?'%J`;5SBOVSU8#E5US%X?NN"1T_F95/'TW/>LQTZ$H%
MVC*@HR2Z<VJU!;!$5+YJ%66APE8]%A7`%PMDE&$=Z1Q3?5]S1-5M?7VKT.I!
MZUI+W,U$?R!SU<SJQG4@^A@U!!`9B*[Z>A!=7'7HN`@8@J]Z8%Q,9;>%I?3C
MO'SJ.3.3OF?/X-OI$(0,%H3T.H(@O(0>,PNPCH!.BK7P\828!S]RC#F/M014
M*W=QC*&WG>/IK8D)S$3J9.+;+BP*KJGTM'W<V3OMH^ID#EUEM?K+UD[I],#H
MR#]:605AIG=)T,D]O5W'*4GUM1]N%#H9UMS^L5?AP7>G9-0IF+O"@/4;N:E;
M8QG/U()ZWUWP8EN+HQ4R^OZH[R>(GD/HFJIU#L>U]@46P`1$Z[J&$!,<K;T1
MT-!.'H>>0PW=9K0W4[Y6YEFFYE[B.G34B[M'1^5^Z%U*_1:LI=Y>V?3#[&SJ
M.2N+OF=10+A($84Z@I!"7\_,9\\@7C,\])%33.+GDS/I0\=H^L!A#;V/`C7^
M^?:$&'K3*<[8S939B<6@@UL6W3\^!NYN+3QH2+_FIA$AAV\>M89NL@UZQ'2X
MV?&&(?GAUR>EA+YJVSSM*]XW)-SVSI3LXL^7[:'.4]*_,QV^$F')Z""=%SM^
MH6TP##'Z[B!Y`+WG46."?CPPLMAJ40O-)00()QUGJN^UB8E]EK%/+KIQPBM#
M7W_U?@*":#BG!2TA0,\@W`M]K_HS$2J#=Z$>!Z+7D1I-$0+U)CYJXEETZ&@\
M;K$)6_+Z[`W4SZ>(^J(KZ)Q<%H0<11!ZL2#TG)EU01"DL%&/*>G4S3/C]^Z3
MT^L8Z<\FQ7?K-C6G=K;1!*,HO&<?15U8&#JQM_`F>PTON^?0?>/6U%TG8-QL
M&^%QJV,F73\B!"[Z)<-KDY(7=/3(*'C#SK\QL=HZZ.2>V*ZS9];&CQ?OI+=<
MDW/XNWFE]JK!SE-:A@9]_1MJL)$6C!;,6F@.(<":A99AQ-:GEN+T2$Y07P.B
M;;4:6D*`M0`M8,-\&'5Y+'8^4T\P+E8(T!Q.O@X;V"]3'<.:B-Z/2T?C<;U5
MD%6[*874>V&QLIL8-H[IBST#6!3ZS,E1O(1>L]A+8$&H'39*HU[>Z^$AH$UO
M+0SR*?[OIRX)>[IZ9&@4J4$0HME+B#+V-G*,I]?&158^9:C=A12XS3;ZWEO'
MQ?]^_:@U^!+40B=#^G]:&0S-D@GR@L'GNI==,W]YS2-KY\NNJ>^;#C<&_^KD
MGF[]IGO&3^_-+2/^]X%.AHB:L$`G`_T'^RY@$QYLZ=G)(_W=M]Q3.K\S.>.E
M]Z85M'F!/R_3T)8`&!+$N64#`R8S&],9U!*:0PCZ,-7WP-X)#0&VVU1?B_>G
MAI80U,ERDX!%:GDLPE+JL./%"D$<4[X."\3(V,)&._+QODP=.AJ'_PSQ>_7>
M"<GT]?PB9=<P-'J#(/2O(PA&+T$.&_6<G4=?3TD_W$.UIP#0U2UYQ#>S"DWU
M"):JEJ/IHXDIU-DN7-,`WS,J:L6]H]?4B>/>9QMT[1-VL9\^[A#7[QE#.MS_
MB\*S+FF?/#\Q.?,Y0]+YESQRZ>4I!<3_CWJ>!>%#KSALA&X6K\[(N_8UU_3O
M7G-++WYKVEIZPS.'WIB<6='1$/?^:^YI[[SAGN[YAEM:XINNJ>6O3TK]Z2VW
M-'K;,YLZ3\VESE-RZ6V/3'I[<OKYM_@\"UN=UMY_$08S9<,"[F0VM)5S0]`<
M0H#PE'S][\R&MH:&IX;U&_EZ4)V4T%@AF,:4QYYAJENC7(P0X#GD=0YLMH.-
M[@%D<,GW0[ML'3H:B5XKK[_1.O3HAUXL!(N*:.CB(J4%]$`(P@+L/6S<7K+O
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MON&62EV\2ND-U^3B=R8GMY1>2EH[DJ%7?'.BJ4*`6?8O3/EZI*XV!J.9\O4@
M=O:2T5@AP`*Q/%:K-<K%"`'6)>1KY.U:,8&2SX%UBC1UZ*@75P\/CGUY>K&R
M3F"U=!V+03$-85$8S((`#T%L2*\.&T$0?F1/HN?,S(H>;)1-MZM!=X_4H3WG
MHFH9V49)4DU";2_ADXF)+`AQ9[7248$NQJPBL_'VQ\=&WOBH?:S#D^-C#K1S
M3J<G[.+HT;$156W'1A6WM8M.?=@A.NEA^]C,A^WCMCQJ'W/JB8GI]+1G(;5C
M/N662X]/2#CSE'.R7SN'V!<1<GIJ0D+?=D[)&]J[Y]+SLS;2\S-*J8/G6GK.
M/8<ZN&73\Y/SF+G4P26-GG6*I^=,[,!\P26%7IB42L\[)]`+"A/I!18)"`7X
MDHFO>N10QRGY]+)KZN)'K"U['I<1"&?)>_B">YB:HMH$-%4(4,^@OA[AGL;@
M1:;Z'C#2,K2$`"$I-?#WB3;I\CC,VM]BJM%8(<"]L=F^?(U<8(GPJ'IG-7/9
M6CITF,=_A@6->-@MG[[S7DM6OAO(:MEZ&@9!6,*"P!["X$5"$+3#1H.6;J9>
MLS/KS-I[!`?_^RO/M,W?SUY;)_U47:36;6H>?>04/=%TZ46!OP'_>MDZY/WG
MK$)\VEN'[&QO$T;/VB51^PGIU,XI@YYR3*/''9*H[9B(/]N.CZUX9$)"^*,3
M$@<_8HC3#"T]/2GUV2<-R2.>=$P(>-(AH>Q)A_A33TZ(IR<GQ"F;](!/F]@.
M=(RG9TQDST(AA*)&+"`,;IGTDF<^/3\I=>,++LEULJ7^8B#<(!L4,(1I#LC&
M04'4%#/$.2P\J]%4(4!1EOKZQF9H8=*!E$OY'NHL."TAP%J")Q/O#[4+,4QU
MYA+$\V.F%AHK!.KU#-1SJ(59[=U`A/#L.G0T`@,"'[MM5/0?'\W*IZ$L`B-7
MEI#U<BU!T`@;L2`,\%E'/\[)/]S#,QF+5[7P[;3,+KWF%2D+S"(%M1N+0E>Y
M2(T%X<O):?2I2_SASWEV;[JTR>@X/++U\]:K7VT_R/^S9P;[=6\W:.67[0:N
MZ/3D8/]'&S(+OW-$U%UMG%+>>]@IR;F-8US\(P[Q58].B/WS48=8>LP^AAE+
MCYOX!!\#GU085R,61J&(I6<FIE+[21G4SI"R_AE#RH`Z^S"T#*#B5C8HH&;+
M<1,^8ZK'J^G"5*.I0H#*9?7UC155M,50%V>I0SE:0F")J+GXAFDI<Z<Q0H#[
MR'LR@^KP%:#E-6AFXNG081%76P47OC1U+?5E8S_:?R/9K"RE$2M,@N"[GH8O
M95%84CML5",(["$,7[F=O8-L9#+4P;?3,Y;U752FU"-H%ZE!$!+IZYF%Z'QJ
M;[KL+\%C@WQN;SM@E4N;`2O+VPX-H4=&);`'D4AMQL11F]$QU&9<+#T\(9G:
M&M+I$>:C+IGTB',*M65A>`2TBZ%'^2=H%(L8>L*00D\Z)>:R`&BE*+8D:(5+
MT#+"'!"B4(]7$U7):C15")#"J;Z^L?M98W'^%%.^ASKKJ+%"`&.\E&DI;;@Q
M0H`,('DL/`]S&_`O8<ICL5"-?8UUZ&@X_C,T:-1#D_+I*Z]\&L5"`#&P]2MC
M[Z"4;&H$80,--Q,V&K2HF,5A_>^]O;/JY/SW]"JXJ:=7[MX^WL5*^BE:66@)
MPE=3,N`I5'_H'G>'Z=++CJ?Z!]WVZ."`@8\,]%_4MI]O\D.]?<O:]%Y:\4"O
MQ97W]5I4<7^O)1L>Z.V[YO[^*UP?'!7UW0-CUA@>M(W:_)!]$CTX+IH>8B%H
MPQY"&Q:`-G;1]/#X:&KK$$]M)\0?>M@AWND1^[_NO34`V%!=G8Z8QC2'>YFH
M+A?$SG6'F?+UET((L%N=^OI1S,8`=0X(H<CW"&?*T!*"A4R\?G<F>@RIX_.@
M!],<&B,$R`"2QV+1^#HFO!DUL6BLKJ!&T9\.'8W``+_[;K*-_.6M*;DTE`V^
M7?`6&AVP21$%VU4L"'XL""M++G@)&H)@[;>5O82"M:8[UD+O69EO]5M03#_,
MR:M=M2P5J4$0OI]3C(KE%K4_,6H<$$IZJD?=6@<C>ES5NM=2]WO[!U#K_BNI
M]9``NL\FE.X?$T4/C(]A1M.#]G'4UB6;?R8<?=`NOK%&ZW(!L6=UNX;&MBY0
M]R2Z%$*`BF*U$0]E-@9:=0CJFA@M(5#GZ6.&CIY*\AAD-)DS[@T5`JUL('@$
MHLF?FBA>4W\F^YGU-<'3H:,VKAX:%/J$>P%],R^?[$.VTKB@+30V<#.-J2,(
MVF$C"(+MZG(:-+_`P73+6N@S.VO<$-^M2@JJ=M4R$XWO9N125[>D.OL=M'3<
M^]U"A_M_]*=[OEU(=S/OZ;6$[H$P#`^BUJ,BZ-ZQ472?0P(]Z))%]XZ/S6IM
M$_2XZ=*6!(2"9&,"SF,V!&A%K1:22R$$6J]SDFFNVZD6L#`L7P^J:UFTA$`K
M?11>L-H(:X9)&0T5@D2F/.YB^7?I?JOC<N$_0_T[W6Z?0IT]L\AFU49R#-].
MXX--@K":!2%P$WL)&UD4RA11J"T(QK"1U?)2&KZB[(\!\PLT#7F?N7E^PU9L
MNU"U+(K4)$'H.:>0ND_)V*A4#U]AN+_GDH0'V#.XM^<B:OV=CU$4OF.R*-S=
MWX_NL@JFNT9%4FOG=+K;/N'$7:/#6MJF_%J90R`R=>K#Y1("`.$7]3V\F`V!
MUB+W7J8Z@:"A0@`@A":/.\'4:EG2$"%`89Q:6!"R0Z4RO`USQ'GY&G`=4X>.
MQ@&+QD^[Y=&WW@5DB-Q%#F';R3YT&]D)#Z&6(*C#1D8/P39P._\LK>CCFUZG
M^Z(A/?T_`Q:N31^^<IOYJF46A!\7EF%O!/1ZOZ)P?^]%3S_0=_GO]_=>1O?W
M6DSW]5Q,K;]?1/=`%"`(_.^[^OC2G4,"Z<YQ<72G?2+]SS8$S=I:$M`L3FU0
M0*0IUH>+#0UACX+&`.$J+(BJ[V.N%Y``%NRU&M4A$TF-Q@@!&M&IQVJ%`!LB
M!%APEL>@LOMAYOT-H+J>`=1*X=6APSRN&A;XQ9V.F?36Y`PVZ)O)94TY30C?
M44L0Q@=O85'83&,50=!81V`/85S87O8.2F)-MZV%03[)-P_T6;?>BL4`]0BB
M:KF/5+7<:S8+A'<Q=?=(:FDSYGKQ0)^EB6T&KJ8'>B^E^W]8PF1!8%&`EW#/
M]R9!8&&XZX>E=(=5*-TV/H%N'A71W-6[30%F]JA>51L4$-6S:$.!L)9(DT26
M#`PSLHB.,N7Q#14"[%&`GE*6",,L0YU5(XA0EGHO;#S?2.9IIGJ\YM\IHS%"
M@/4C>!7R6/1L4J<)UR<$>$[UO@ICF0V%UC.O8>K0T3A<8QV\[@G77.H^)X\F
MQ>PAYZA=Y!2YDQQK"<(VLV$CL8Y@%[F/K'U+L)M2'?3URKIC\)+UI=:K=EQH
M8Z&N6O8NHA^\"DY\[Y&,V=`5@[;]?`<^.C24'OIQ&3W89YE1$'I#$);4"$)K
MDR`@='37@`"ZR2;JW%7C8IXTW:(E`(N,:/NA-BJ"R%#9QT3+9V3.:,W.0:UT
M8"TA:`BU%H21&:,U%L^WA9G#7,_4$@`0:P7F4C(;(P2`5C,[U!7(J$\(4'<A
MGT=*:F/30'.9\CWP633'#G`Z_DFX>FC@^[=/2*=7)J62U:J--#E^+QG8,W".
M*F=!V$6.$3MK>0GF!`&>@GUD)5DO7S_&=.M:&#YW[?^&+%M?,#)P5ZVJ912I
M*8+`'L*`Q:74>T[^QA[SZC:V:ZEXK/_R]H\.7$6/]%]!#_?UI38_^BJBP)Y"
MC2#(8:/6WRZ@>_H'TBW#@@I;48MK78VU`;2?E@U+8Z@UF]7J\],0FJMR1BHG
MJGFUKC%'Q-Q1^6QI'0JQ>O5U$#%S0#KM;TQY/(12K@1>S93/@TC;!;"FH*YM
M6,YL++0RHB[F/CK^Z;C&*CCAX4EY].&4#)H4NX?<XBIH8LQNFAB]VZP@U(2-
M6!",8:.--&;U%K*/J("7@!SS.D!SNN&^);&C@O8HE<N*(-0TNS,*PA#?+=1[
M7FY2CQX]FKOGS27!$\-7_._Q02M./CXX@!X=L((%83FU[;><VK`H&+V$I77"
M1O=]YT.M!X70S<."ZXMQ_Q6`L43H"L8$:P!8F%0;&D&$AK*9Z,2)4)'6+ET(
MZ<!P-Y:6JIR12X\V)YE,M3$5Q.P;AAG/I@X=:0$M--3/@`U[+`%M)^3QV-?Y
M):8`/&3Y/*J11:OJKYE(^13G$%JZF")$?!;8JT%^'>SAW*3]-G3\`W'5\,#'
M;AX3<_X9YS3Z@0WTM-0#Y,IB,"FV@EQB]BB"8/02M,)&$`21?KJ)QH7P\8@]
M9.M?9K97NM6RDGFC@LIIN&^ITL:B=K.[/$*F4=]Y^<&FX2T:[4>OO/Z)07Y5
M3PU;3?R3'ANXLI8@P$NH&S9:3`_\Z$?W]%Z\N5ZOP#;OVNM[S;_SKF]\'[K[
MA\5//M!WZ5./#`QLVV%X@#`HEQ)H<H89+/;[13\="`2(K!_L"*9E^-7`/1`[
M;RP;.A%`*`4;R6-]"<^&_9"Q&-W0O8$%\'M0/T-#]L"0QV/M0,Y&PGN0SX/B
M]XTU%_6YBX7ZV7'O*RX+3T<+P-7#`R?>XY)/+QF2:$SH=IJ>=I#<$O:26_Q>
M,X)@+FRTF>S"^'A4!7L)94-,MZ^#X;[KAEBOV/SKR(`=QC86JF9W5G[;J>^"
M0G_3\!8+",$S0U95/6,53$\/645/#O93!.%Q%H3'%$%842,("!L]:`H;*>R[
MDN[IL_B%IPR;;GC,?5W[1SU+NCWLMFY\:Z>LQ;?;K$FZO;]_V5T]E^R_K^>B
MTP_V\3T/D6DW-(!>&1='K]J$8#:J0X<.'<V(03[_O=8F?&.;B3G4V2.-)B?O
MHZGL&4Q.VD?N"96*(!B]A#TL"A`$\V$CA(SL60R<8P_0V*"MF@5GP/`EZUZT
M6;6Y9&SH7O8.2FHUNX,H8'%YX,*B\!X:.YJU%+0?$G;G<U;^9YZS#J%GA@6P
MH?97!.&IP:N,@C"(!4'R$AZ6PT;L(3PP/'QO&[?"J@=9A.]SSJ?68U+HGJ$1
M=%__`&K3;Q4]-HCOQ]Y&AQ'!].JH,.KL$$?O38C[]1-#S!6UJ*Y#AXXK!-<-
M]'O^EK$)OS_JF$I=Y^;3[*S#BAAX).\W"D(B"P)["1<$H6[82!8$A_"=Y))P
MB,:%[?`QM]5D']_T:T:NVCS#-F`KC5J]LTZS.YN`72P.Z])Z34MLD4VU7ARQ
M^J471X73\VRHG[-:3<\.#Z3V+`C/0!"83TE>0IVP$7L%#UF%T]VC$^C._JOH
MGIZ+Z8%>B^B1OLM82/RH`]_KI9'!].:8<'K'/HH^<HJE;V8745?7!,T%>1TZ
M=.AH%EPS/'#4G89<>MP^GOJO**5Y><=H:MI!FL*"X)FRGT5A'TUF07!7!,%R
MV`B"X,#"X)I\E`6B/&V<7ZG9;2:M_$K?9#'(0TW"2/\M+`C%QMY&+`@V`3MI
MR-*2G?WFYJ!C9HO"*R-#;3HZ)-*+-L'T@DT0/6\=1!T@"%80A,`:+T$6!!$V
M@BC`,T"**43A"3[^[/``>@W&WRZ67K>/4?9]QDYOW=R3J/?\]?3][.P":GG9
M1CITZ/B[X3KKH+#6+@7TI'T<C6)#/C__.$U+KZHK"!IAHPN"4#MLY)ITA!S7
M[#Y@%[K=W"8>"FS]-PVV]=^R=WQ$)=FLVFQL=K>XB$:LVDK#EI6=&[RHJ+]I
M:(O`JZ-"L]Y@T7S%-H1>9F(&KPC""!8$Z]7L)00J7H)FV(@-/_@L'W^%KWES
M;"2]X9Q,'9Q3Z9Z189N?<8C>W'-FCE*!/="'/X=E)6='+%O_J.FE=>C0H>,2
M8MB\&VX<&;7Y/O8,VCG&D3,;^OD%QVEZYB&:GE'%HG!0"1E-2;$4-C*FGPHO
MP3%B![G$[:>)3,?(7=.L+6P6/\BG^.91_ELGL(=P<'QX)2%L-)P%P7K%1K(-
MW$G#?$N6]Y^1T)BF8Y<$G<9$//>V??2?;XZ+I-?'A-%KH\/HE5&A-8(`+^&"
M(%P(&QD%P9^>'+22VH\,IQ>=4OAS3J$'QZPY<]N8Z#7_-S+JZU8O>]WTY?3T
MS<.6HGJ[A$:%[J$><W*:NST%-JG'YXA40Q#_1CJBI8P3G,,XL+Y,%VP\A'$-
MW8`(64CB>>H#7EN,E9^_(34HXKG`AF0^R<#?K?RZ#<EN$M>`3?'FQ&>/'=?0
MXEQK[4S]?%K$>?EWC&<2G[VEC78`O%_U/;1^%^8HQHE0,5IMXUB=C:XL`-?B
M'N)S,&M+5,#[Q&N!#>G4>C'/)H#?#3+[VC#1#@3WNO)PU>!EC]X\)N;XO8Z9
M]*PA@2:SX5^P]@3-S#I,,VH$0<-+J!$$C;`1>PC.:W:31]H)%H>*$OO0K=B/
MUBQL%V^Z;?3JK:-M`[;L&,>&<$QP.8M!&8T.WD/6OAMW#UVRX2]MU=!Y?&3T
M!RYIU'E\!'4:%\$S^@@6A'!%$-A3J"4(+[`@U(2-3(+PK%40W6L3LNOZT6N6
M_M_(R)ZM!D>C2$G!@W9KA@T+W$7V05MH0OQAZC(]0[-JNXE`KQHT3$,W3Y%_
MC\I4[#.0PD3_'`B##.3)XQKP`QRP@"@FQD4H_[,,[)B&N@0\"_H#6?0<&>BI
M@WMCK-R;'T5>:/^`UT2=AI;A#6.*]WV,V=#>1S!X:+N!V@7QVO75*,!P%C#Q
M6M@CNK&[B2$I`(5ZV#93O?\#G@.5U/*VKWC/>#90'JOFZTP!&-5R)JX9AP,6
MT):)]XVQ;^```SO&J>^/^A.,`W\W'1-$6PWQMXX>8[@7:B$L34"0QHRV(7',
M@TSY?J@DQWX.J!FQ!&3:X7>`WP7&UR<&\K/5-^D1P'<"Q9#J]BMH\8[?54OL
M0FP9UPQ:_M:M8Q-_;6V?2L]-3*0I;/@7%E;3K.PC"B$*TS,.-2ALI%Y'<$LZ
MK'@(SC$5"\8$;]+<R%[`VFO'U:,#MG8?%;`E=N2JC>?'A570^(C]-#JHG*R6
MEP4.7%B$/\[+BO?M(K[YU#6#WI\03>_9KZ%W[*)8$"+I;1:$MU@0WF!!Z&@2
M!*VP$1:7VUL%_?;XX,"Z^>[/&F[I,CWGR-2D`^2:7DVO3\F(-)UI;J!6`W^D
M^-(N8Z(!&JIA48@E_H!15/8(4Z`C4YQ#SKXE9#,Q#H5?]4'=BKF0:0GXPHFQ
M,/KH1HHO.KZ$%4QQ+H&I_L*G,W%.""!>NR$05;RR\-39G$D%M(868T%T&D7Q
M6GV`US*'B<(X<2W::."]8M.:%4RTS("A*F,*#&.*\?B=XAY:Q$Q5`+->L?WE
M)!RP`!@R<7_TA`(@XNAQ)!-%;6(<?O_R.;0/^1\3$(WS4%RG)028[</`RSV9
MT)@OFHF_5Q0^HE<6]FE`,9TYCPLA5?GW!N*SL@3YV1HB!!!D<>^M3&QLY,9$
M<23^QB#<5V;[CVN'^G]YFUT2W6V70NU9##S3#]*BHFJ:G7-4H1"$&B^!!0%A
M(T]UV*A.^FDY361Q\,RHYG]7''&.KAQM&Y17GUO::JS_YD=M`[>.';EJ4Z[U
MRM(_G!-/DFW`=K):43IMD$\QMB2\Y/C`,>KISUQ33GTZ*9D^=(RA#QRCZ7T'
MHR"\RX+0!8+`?$OQ$L)-82,6!,E+>&5<#+4?$81-3NK@5IL0[TGI)VA&P5EZ
MR3,CAR=#EVK#D0`F_FA1\:H&.FR*+Q]FHP(H+A-_[*@FM@31KAG>A25@=HIQ
M:*V,JG31NL&2Q_$>4SQ'!QR0@-`!#)HXKZYG$4WV4*<B-K5_@6D),%+XG#`6
M8BF,"EI3F`.N$1U:T9M([(M07PL(A#LP"\58$/L=F!,/_&V@?Y$P@&@2B&M@
MV!L:,H$00%!PG0$'+`#/(9[+DD>/,*88)]IJ:&$^$V-06:T6`H@AMA05]X$W
MI6Y&*`!#+7\.:N`SQST@()ZF?VNU(Y<A/UM]0@#/4#RGN<\0H5A+7D_+QC5#
M5GW_/_L4NG-\,CWA%$>N;.`7%YTDK]RC1BJBH!($#2_APCJ"%#9B07!-V&\4
MA-B].R;&[!W<$$$`QH;N>G2D_Z9!-OX;(T>LVG3:9N660R/\-GM>R@75#QPC
M'_]R<FIEMRE9].G$./K$$$<?.\?21T[(\&%18`_A?0<6!/LH]A(B%2_!&#:"
M(%P(&W6<D$2/C0BJN_#]R9PWO_';0MZE?]`S[JE%/`EM;`R[,1!"@+"`5JP;
M7SR<A\>`3=.!2R$$PD"*`D+,&O%_-%0S!UD(M`P28K0(`^`\9HXRA!!`((2!
MJ&_7LYY,C$.81][CP)(0H$4%QN`Y($XBA`*AL^3%BN>#-X#7:@R$$$#@&EI]
M?BF$`*V^Q3A+GY$E(9![-9GM5-``P!Z(R07"@##(8C\'K9;D`HT1@FY,\:RH
MNO][XIJA@=_\;US2'W?8I=*#XZ/)@6?V2]9)8F`B!.%BPT;N254L""?($+UG
METM<Y1C[J')A?.H%ZA%L@[:_;+MZQTCK%1LG#/4I?-<VJ+)!@M)0='5/>:^[
M9\;A'M-SZ0O71/I\4B)]YI*`3?C-"H(<-H(@O,6"\+9]+'48';Z_U:`UM1>0
MGC+<\+Q'^FZ'W%_H$:>DW%8W?X_8[:5$?4(`MQ;G$>,573-E(5#O\J4&!`#C
M+`G!6TR,P0Q;S/;D\%,7'-!`?4*`OQT1[E#OYRL,+8RF,&QX?7/Q?GPV8K_B
MCYCR9V#.R,&H(82!,:XXP)#O@["-%M"^0]Q;JYMK?9`]`A%^J0\M40BP%B6N
MQTYZ30'":+B/O+4NPC;B=<T5K#9&""#LPDLL9EIZSU<VKAWJ_]FMXQ+/WN&0
M0;?;1M#@H"VT=-TIFIMW3$,0M,-&1D&P$#8R"<*4S)/L+>PY;HBIG.\2OQ]?
MO$;!.F['U3V"2<NX-1H]#,$W?#LCR^/;F;D$8O-]\$OW)/K"C:F(`@N"2[SB
M)7S,HO`1B\*'+`I&0;BPCO`N"T)GEPQZP#9\H.GV-;AE1'A(9[_]=,^XV/A6
MK5ZX'%D&0@A@L-1`I@-BKCB/>*?XDLI&$.X_#*XYHBTTQED2@@PFQ@0I_[L`
M$<?'3RW(0B`W>@,@**(],^+J"+7($$(@%D:%1P*#H87OF#B/,`\@;ZAO[@LO
M]D]`7%@.68KCZ(BJ51V.^#_.H]7WQ80ZA1`@K(>9J=;O13W!:(E"("8A6%-I
MBE'%\XK%:MF#A>'&[P#'S:6D-T8(@!%,C`=Q;US?DMK--Q^N'>+WZBUC8P_>
MZ9Q+-UB'T><^A;2P\(22403CKRD(]86-:J6?BK#1;B5D-"6CFB;%'R!#S-[B
MB3%[)Q@B]CQG>I1+CIY><3?U]LH?VG-._JX?%Y;2=S.R:S;?[^Z9JFS`#T'H
MZLZB4",(1B_A4RTO@3V$3UPSZ(G143PSJ5T4=M.(4,-M;L5TC74H9C^:5=B7
M`$((D(6!>#R,:U<F-G87816XU'*L7A:"AM*<$&"VC_/XLF/;3!GRANY:63VR
M$&`&AG4,O`ZR0?#,,-J(RVMY54((L$$.@`PD_!]?7GD1%<#O0K3F%GL"(UM-
MO+:6D8+1$-X`XM$R,/L4B]DP^FI@817G\)H7`R$$EHCPEHR6*`0(U>$XGNMB
MTC<%Q)X06MMX^C%Q#K\K^;4%&BL$`/:D$&M)(/X6\0SFUC:N7%S==^G#-X^)
M*;YK8@$;K@AZWB.-#785+2FN&RJ2:0P;'691@"#4'S82ZP@N,17DGGS(N(X0
M74'.47M*G-;LF6V(WONY0W1E3<IE<\!V1MZU`Q85O]EOP=I9/WJOW3=PR4;J
M.[](V7Q?V5I3WH"?!:&'(@BI+`@IFH(@AXV^F)1,'1R3?FEE'50K!'&33=C@
MF^U2Z,:1D9;ZWU\*""'0(F*HR%!!9T\9LA#`^"+$88XBS<^<$&0S<=Y7^5]=
M"&\!AEL-60B0JG>`*6](@V=#+%@+:B$`A/>B;N;7@XGC$!;A8<KIDEI&3LSZ
MD<FBY=DAQ1/GL?:B7DB5/9F+@1`"&"#$V+5^+_+[!F0A@'A:`N+M&`>:"]L!
M314"9,KA>%.$`**%SP$3#?R]J('/7B1$("-,C8L1`@`+^/@;*&'B>A#K/>H0
MY=\`GQJNNVEDA-]=AERZ:4PBW6L?3U9A.U@,JLD[_YBF=R`HKR/4#1M!$,R'
MC2`*;DE52BT"4E`=(W;]Y!"QJWA"Y*[%]F$[A]N%['A_7,2N9VR#MM\[-G+K
MC8-\BC5^@?0OK!^,""B[:\3*DG;#EY9\.FSI>KO!/D5A@Q<5[AVRM)2PSS*J
M>;6VUOR>1:&6(&AX"2)L]#E$@07A*_[W:Y-SZ;H18;46O6ZT"?WQQA&AE=?;
M1/P5>\T*(3C$Q$P&/?+A$2"+QUQO)UD($-^W!)$2JB4$[S)Q#G%5+,3"6"`5
M4Q`>`F+DXK5>9<J0A:`3#C"0`8)G%]M(PKAK04L(1#HJ#`.VD`3@M2$U$\?E
MO0DL"0'^WL2F_C#$2!>4WQ>(]X+\>HQ1Q[_%3G%-#0UAC:"AV6982Q`>8'WI
MHPAU8!QHZ6^VJ4(@]M+&WX>EZRU!>`.XM_IW`.)W([*29*$7N%@A$,#]$"Z2
M4U_QN?S]<+U5D-5MXQ-_N<,IEVX>'4OO>Q?1##;PBXNJ:8Z&",C47$=`U7*:
ML6JY;M@(@E"[)F$B"X-KPD%R3SE*;LE'R!"[7^EO-'[UYG/C5F\Y/#9@T^[1
M@1LWC?8O+;%=55(TTJ]TX\@59=NL5Y3NM_9=?X9_DFW@#AH5M)O0$GOX\C)C
M!U33'@EHB:W>6K.W%P0AV^@E*(*0R8*0P8*0KA$V2J*O^=]O3"TB-O8>IH^-
M_R3H7S?;A'=C$5AXPR#_RY+VJ@$A!%KIH^8@"T%3LH;46RS6QUBF#"TA$)##
M2LCF4$-+"``4B^&X".>(3!!\/K*1L"0$_9CB7$,(SPOK,0(BTPALS/[%`D((
M&I,UA*0*X;TA=]X21#@/5(?S9#15",1$`42-2&,AO`%QCX80._3):*H0".`[
M(SPN"/3?$_\=Z/?\S6/6%-SM4D"WCDNE1UPR:$CH3EJX]KA"+1%04X2-C(+0
M\+"17*1F[&W$Q,_(<N9N<HS:H^R-,"%R#SDP[<+*:3P_VYB@[30J8#.-]"NC
M$2M*R,IW`PU?MM[8VPC-[I26V(5*2VS-K3792^AM\A)Z*EZ"*6S$@O"-21"^
MF9)*W_'_7YU:3-?91-8*.=P\,O3A&VS#U0;L<D,(@;FL(2TTAQ"(S!C,]AR9
MMA:(L)%X/;GIH"P$6K'J;";.(<2B?F_FA``%<CB.V3$655'G@?^K=RHS)P0P
M%O@L<3R&B4I8K?<$8J%:S!2Q`;\`9O%8G,=QG$>64F-P,4(`B,]$*W%`!HK1
M,*Z*:2DKKZE"`&],)`S@[P0+]HV!B/\C2PLA5ZW?`8C?D?B\\;<BK\\UEQ``
M2(;`O<"_,WK\^X:1X8;_C4WX]2Y#`=UIET9OSBXFQX1][!V<4'H5:0F`FEIA
MH]J"8+Y(#:)0[]::06)KS4W*/LNVJ\0&_"6*(%@OWT!6+`CH;826V$,6%]?L
MD3"0O80+6VNREV`*&PE!D,-&/\S(4#*,GO$LHO^.B$!!4&T8Z'(M"%O"7R4$
M2./#<;1ZJ`]X+A@=C$?+"H'ZA``B*\YCEB[#G!``(JZ+L`YBRS",ZL_&G!"@
M&`[',,NW6"UO`@0`XV'PY;4N+"S*[230Z@`S7"U@#4+V*"XF-`3([PFOIP5X
M6B+_7J3$FD-3A0"`D(ET6Q!CS7DA6(07*<ZH?A:90ECCJ0\(AXK70(A40#Q;
M?>((8.)@KB@1"2Y8P\*]\)W[^^._@U<_>\.HR,0[G;/I+N=\>M`YAS[QV4BN
M*0<;*0AFPD8L"$K82!:$6LWNU%Z".4&0-N!G01A5(PBE%P3!EP5![268-LVY
ML+5F[;#1CU[9U'].-GW&(GB_4P;]W_!0].MIJ1"S%.RUVU`A:$R+"1%_Q:*O
M@)QQHT[[-`<8;/4U(J8/FENTA`#A/,(><C,Z(5!:BW=B<5A0:]]BV7`@U@S`
M(*,5`8[5%UX10'L1$;Z`T9&!MA[HJR->!\2,%<5V\)*PEH#/%2$'.<5V*%.,
M-[=8#.+WJ,9<IK@6ZRNCF=\R8=3%I`'$Z]97HX-B/3%>?$9:$$6+^YAJ(0"0
M^BO/ID&$ZN!QH1@018A(_X5PBLP@48B&M1JM>ZJ!29GP"B`\8O8OG@WBA]?2
M^AR%:(J_&SP;6K<@G(7/4_X=8KVIH;4=?P]</SSH^YM'16^[>V(!W>V41VTG
MYM'GBS>12_(!6L2"@)!1?6L(@@T+&V&/A$IRM1@VNB`*=B%B:TU)$`)8$/S+
M+G@)+`@C%$$P$S9:>"%L-)"]A"$+\NF'>07T\HP2+*#O:S7`'\:J)0-_R%B4
M1%^8A@H!LHAP#8@0CR4@KH]Q*.L'\*6$$<%LM3']DY`"BIH&A#NP``C`"Q#/
M86[1&MX+^@DA8V,X#I@`SP+7:8DTC`(\%KP6#(N6(4$=@7AMD1:()`!D`2%3
MJ#&]KR``N`\,F58&'-X;#`K28G%_851`I+O"V,DIG_!^<#]\QO)8-9&YI`5X
M-7*VBTPLPF,QN2&M*_!YJ#\C+6!1&&/0W\J2T<;?'8PN?B?RXBN(V3_^/K`&
MA_1?A/9P3[R7A@*IP;@&GS&$'A#/IGX]F?B]X6\&SX=P).I&U&.P$(W?44,Z
MX_X-T7W&M=>/"+-E0=AW]\2U=)=3/CT\,9<^7%A&=K&5[!T<4T1A7G[=@C0M
MU@D;U1$$DY<@52U?Z&W4@+!1C2#4'S8R"D(Q#<->"4N*:,#"(GIG]GIJ;<BA
MJVRB`EM].QNN8DL'TO+PG(U9K,9L"=>`]1D$&'",$[G\$!ML3H1CYJHYS4$\
MJXA[XWKQ');NA1FE&"<@GLM<>BEF]SAOKJ@/[UO<4Q@O\3I(Q6P,\)G@.HB`
MN=<30+L1I#PB]($PB+HS+("9NG@V2ZPO;(10%!9L$?[#A`;AG88(@(#\')8,
M/-X#QC3F;Q#7X/V+ST%.+T5_(OR-X)Z-A7A>,6L7SV:)>&ZY)@B_0X@1BOG@
M"<EANW\X^LRZY;H1H>-N'1V]YRY#'MWE7$`/..=2QUGK:&#03IK"L_Q%A2?(
MAZE5I:RF9MB(!4%SCX1:@E#;2S"_CF#R$E@0$#:Z(`C&L-&(%1O(ECF*V7_1
M.GK7:ST]Z%9(UXZ,W?KOH8%:62HZ=.C0H4-!KY77LR`,NG%4]+H['-+IKHF%
M=+=C+CWI5D`?L9=@$[F'IK-QAR!`&+S98Z@_!54.&VE4+2-L)-81&A`VL@_5
M#AMA@=EN]4:R"]S(HE!&/7TV4,>9Z^G>26OI:MOH?5=9A8YNU=VVOKBI#ATZ
M=.@0N-HJJ,L-MI$K;QL36WTG>PEW.J^EUDZY]/3DM?3!@C(:'%*N+#`C;(3P
M$<0!"\WF/(:+"ANQ(&B%C1Q9$)R8AHCM"AW96Q@5N)EZ+RVE=WCV_[CG.KIM
M0B9=,S)JRU7682-;#?)I2@F\#ATZ=/S#,<SW[NM&A@VXP38JX=;1L6?O=&91
M,*Q5%I@?<<FG5V:LHR^7;J:AH>5D2-Q/,]G80Q#@,8A%9_P?U<P0"7@0BBB8
MRS8R>0DH5/-@3P'T9&]!87P%N<?N43R%L:$[:*#?%NJZL%29^3_BL8YNYV>[
MSC;ZS-4C(L*NM0G[O%4G@Z78IPX=.G3H:"RN&1'\`%HPW#@R(OB6T5'[;[=+
MH3L,!70'>POW..53&Q:&9ST+J=.<#=25Q:'?ZITT,JJ"G!)XMI]6I50TPSN`
M%P%QP&(T!,([CX_E'J$YV8=IEN(M'%0\A(EQ>VE\U&ZR#ME)??VV4;?%&ZG+
MG!)Z?MHZ:CNYF.YR*:2;[=+IVI%KCETW,CSJ.NNP`==:^V&Q4X<.'3IT7'+T
M6GG]-=8A'=E;&'.C37CX+2.C=MTV*OJWVQTR>6:>KXB#$DYBH7C(I8`><UM+
M[3V+Z,7IZZCC[`WT]MP2>M>[C-Z;7T8?+=RHA)O>F5=*;[&A?Y5G^,]-74=/
M>!330VY%U'I2$0O.6KIU0C;=-#J>;ABYYM`--N%IU]N$NU]G$_I!*]N@QF:"
MZ-"A0X>.9D<GPW^NM@YL>]V(T(^O'Q$Z^D:;,)\;;<.3;[:-W'*+;>216T9%
M_7+KF#BZ=7PRW<JS^%M9,,#;V+C?ZI!%M]AGT,WC4^FF,0ETD\V:/VZPB3IY
MP\B(W3?91.3?8!V^^GKKT$G76X5\]U^;X.=:6?MII>7IT*%#AXX6"S;<UPQ:
M\<!_AZ]ZYAJKU:]?/=S_@VNM5G]Y[7#_KZZQ"OSFVF$!W:\='M15.3XLX)6K
MAJ]XK!4:O0WR:6K_$!TZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0
MH4.'#ATZ=.C0H4.'#ATZ=.C0H4,;K5K]/^G9<LP&C7V#`````$E%3D2N0F""
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
